Common Bile Duct Neoplasms: Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Bile Ducts: The channels that collect and transport the bile secretion from the BILE CANALICULI, the smallest branch of the BILIARY TRACT in the LIVER, through the bile ductules, the bile ducts out the liver, and to the GALLBLADDER for storage.Common Bile Duct: The largest bile duct. It is formed by the junction of the CYSTIC DUCT and the COMMON HEPATIC DUCT.Bile: An emulsifying agent produced in the LIVER and secreted into the DUODENUM. Its composition includes BILE ACIDS AND SALTS; CHOLESTEROL; and ELECTROLYTES. It aids DIGESTION of fats in the duodenum.Bile Duct Diseases: Diseases in any part of the ductal system of the BILIARY TRACT from the smallest BILE CANALICULI to the largest COMMON BILE DUCT.Bile Acids and Salts: Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones.Bile Ducts, Extrahepatic: Passages external to the liver for the conveyance of bile. These include the COMMON BILE DUCT and the common hepatic duct (HEPATIC DUCT, COMMON).Bile Ducts, Intrahepatic: Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.Common Bile Duct Diseases: Diseases of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.Cholestasis: Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).Pancreatic Ducts: Ducts that collect PANCREATIC JUICE from the PANCREAS and supply it to the DUODENUM.Gallstones: Solid crystalline precipitates in the BILIARY TRACT, usually formed in the GALLBLADDER, resulting in the condition of CHOLELITHIASIS. Gallstones, derived from the BILE, consist mainly of calcium, cholesterol, or bilirubin.Adenoma, Bile Duct: A benign tumor of the intrahepatic bile ducts.Cholangiopancreatography, Endoscopic Retrograde: Fiberoptic endoscopy designed for duodenal observation and cannulation of VATER'S AMPULLA, in order to visualize the pancreatic and biliary duct system by retrograde injection of contrast media. Endoscopic (Vater) papillotomy (SPHINCTEROTOMY, ENDOSCOPIC) may be performed during this procedure.Hepatic Duct, Common: Predominantly extrahepatic bile duct which is formed by the junction of the right and left hepatic ducts, which are predominantly intrahepatic, and, in turn, joins the cystic duct to form the common bile duct.Cholangiography: An imaging test of the BILIARY TRACT in which a contrast dye (RADIOPAQUE MEDIA) is injected into the BILE DUCT and x-ray pictures are taken.Cholestasis, Extrahepatic: Impairment of bile flow in the large BILE DUCTS by mechanical obstruction or stricture due to benign or malignant processes.Cystic Duct: The duct that is connected to the GALLBLADDER and allows the emptying of bile into the COMMON BILE DUCT.Cholelithiasis: Presence or formation of GALLSTONES in the BILIARY TRACT, usually in the gallbladder (CHOLECYSTOLITHIASIS) or the common bile duct (CHOLEDOCHOLITHIASIS).Thoracic Duct: The largest lymphatic vessel that passes through the chest and drains into the SUBCLAVIAN VEIN.Cholecystectomy, Laparoscopic: Excision of the gallbladder through an abdominal incision using a laparoscope.Jaundice, Obstructive: Jaundice, the condition with yellowish staining of the skin and mucous membranes, that is due to impaired BILE flow in the BILIARY TRACT, such as INTRAHEPATIC CHOLESTASIS, or EXTRAHEPATIC CHOLESTASIS.Biliary Tract: The BILE DUCTS and the GALLBLADDER.Cholecystectomy: Surgical removal of the GALLBLADDER.Biliary Tract Surgical Procedures: Any surgical procedure performed on the biliary tract.Cholangitis: Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.Ligation: Application of a ligature to tie a vessel or strangulate a part.Choledocholithiasis: Presence or formation of GALLSTONES in the COMMON BILE DUCT.Sphincterotomy, Endoscopic: Incision of Oddi's sphincter or Vater's ampulla performed by inserting a sphincterotome through an endoscope (DUODENOSCOPE) often following retrograde cholangiography (CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE). Endoscopic treatment by sphincterotomy is the preferred method of treatment for patients with retained or recurrent bile duct stones post-cholecystectomy, and for poor-surgical-risk patients that have the gallbladder still present.Gallbladder: A storage reservoir for BILE secretion. Gallbladder allows the delivery of bile acids at a high concentration and in a controlled manner, via the CYSTIC DUCT to the DUODENUM, for degradation of dietary lipid.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Biliary Tract Diseases: Diseases in any part of the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.Salivary Ducts: Any of the ducts which transport saliva. Salivary ducts include the parotid duct, the major and minor sublingual ducts, and the submandibular duct.Liver: A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.Cholangiopancreatography, Magnetic Resonance: Non-invasive diagnostic technique for visualizing the PANCREATIC DUCTS and BILE DUCTS without the use of injected CONTRAST MEDIA or x-ray. MRI scans provide excellent sensitivity for duct dilatation, biliary stricture, and intraductal abnormalities.Bile Pigments: Linear TETRAPYRROLES that give a characteristic color to BILE including: BILIRUBIN; BILIVERDIN; and bilicyanin.Ampulla of Vater: A dilation of the duodenal papilla that is the opening of the juncture of the COMMON BILE DUCT and the MAIN PANCREATIC DUCT, also known as the hepatopancreatic ampulla.Bile Canaliculi: Minute intercellular channels that occur between liver cells and carry bile towards interlobar bile ducts. Also called bile capillaries.Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.Biliary Fistula: Abnormal passage in any organ of the biliary tract or between biliary organs and other organs.Wolffian Ducts: A pair of excretory ducts of the middle kidneys (MESONEPHROI) of an embryo, also called mesonephric ducts. In higher vertebrates, Wolffian ducts persist in the male forming VAS DEFERENS, but atrophy into vestigial structures in the female.Sphincter of Oddi: The sphincter of the hepatopancreatic ampulla within the duodenal papilla. The COMMON BILE DUCT and main pancreatic duct pass through this sphincter.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Cholestasis, Intrahepatic: Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).Mullerian Ducts: A pair of ducts near the WOLFFIAN DUCTS in a developing embryo. In the male embryo, they degenerate with the appearance of testicular ANTI-MULLERIAN HORMONE. In the absence of anti-mullerian hormone, mullerian ducts give rise to the female reproductive tract, including the OVIDUCTS; UTERUS; CERVIX; and VAGINA.Gallbladder Neoplasms: Tumors or cancer of the gallbladder.Bile Reflux: Retrograde bile flow. Reflux of bile can be from the duodenum to the stomach (DUODENOGASTRIC REFLUX); to the esophagus (GASTROESOPHAGEAL REFLUX); or to the PANCREAS.Choledochal Cyst: A congenital anatomic malformation of a bile duct, including cystic dilatation of the extrahepatic bile duct or the large intrahepatic bile duct. Classification is based on the site and type of dilatation. Type I is most common.Liver Cirrhosis, Biliary: FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cirrhosis involves the destruction of small intra-hepatic bile ducts and bile secretion. Secondary biliary cirrhosis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.Biliary Atresia: Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.Neoplasms, Cystic, Mucinous, and Serous: Neoplasms containing cyst-like formations or producing mucin or serum.Choledochostomy: Surgical formation of an opening (stoma) into the COMMON BILE DUCT for drainage or for direct communication with a site in the small intestine, primarily the DUODENUM or JEJUNUM.Drainage: The removal of fluids or discharges from the body, such as from a wound, sore, or cavity.Pancreatitis: INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.Biliary Tract Neoplasms: Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.Bilirubin: A bile pigment that is a degradation product of HEME.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Cholangitis, Sclerosing: Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.Adenocarcinoma, Papillary: An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)Cholic Acids: The 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholanic acid family of bile acids in man, usually conjugated with glycine or taurine. They act as detergents to solubilize fats for intestinal absorption, are reabsorbed by the small intestine, and are used as cholagogues and choleretics.Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.Jejunostomy: Surgical formation of an opening through the ABDOMINAL WALL into the JEJUNUM, usually for enteral hyperalimentation.Jaundice: A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.Liver Neoplasms: Tumors or cancer of the LIVER.Kidney Tubules, Collecting: Straight tubes commencing in the radiate part of the kidney cortex where they receive the curved ends of the distal convoluted tubules. In the medulla the collecting tubules of each pyramid converge to join a central tube (duct of Bellini) which opens on the summit of the papilla.Cholagogues and Choleretics: Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic).Liver Diseases: Pathological processes of the LIVER.Pancreaticoduodenectomy: The excision of the head of the pancreas and the encircling loop of the duodenum to which it is connected.Nasolacrimal Duct: A tubular duct that conveys TEARS from the LACRIMAL GLAND to the nose.Cystadenoma: A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)Hepatectomy: Excision of all or part of the liver. (Dorland, 28th ed)Skin Neoplasms: Tumors or cancer of the SKIN.Cholecystitis: Inflammation of the GALLBLADDER; generally caused by impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, or other diseases.Lithiasis: A condition characterized by the formation of CALCULI and concretions in the hollow organs or ducts of the body. They occur most often in the gallbladder, kidney, and lower urinary tract.Anastomosis, Roux-en-Y: A Y-shaped surgical anastomosis of any part of the digestive system which includes the small intestine as the eventual drainage site.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Ejaculatory Ducts: Paired ducts in the human male through which semen is ejaculated into the urethra.Lithotripsy: The destruction of a calculus of the kidney, ureter, bladder, or gallbladder by physical forces, including crushing with a lithotriptor through a catheter. Focused percutaneous ultrasound and focused hydraulic shock waves may be used without surgery. Lithotripsy does not include the dissolving of stones by acids or litholysis. Lithotripsy by laser is LITHOTRIPSY, LASER.Dilatation, Pathologic: The condition of an anatomical structure's being dilated beyond normal dimensions.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.Cholic Acid: A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.Endoscopy: Procedures of applying ENDOSCOPES for disease diagnosis and treatment. Endoscopy involves passing an optical instrument through a small incision in the skin i.e., percutaneous; or through a natural orifice and along natural body pathways such as the digestive tract; and/or through an incision in the wall of a tubular structure or organ, i.e. transluminal, to examine or perform surgery on the interior parts of the body.Intraoperative Complications: Complications that affect patients during surgery. They may or may not be associated with the disease for which the surgery is done, or within the same surgical procedure.Iatrogenic Disease: Any adverse condition in a patient occurring as the result of treatment by a physician, surgeon, or other health professional, especially infections acquired by a patient during the course of treatment.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Sphincterotomy, Transhepatic: Surgery of the smooth muscle sphincter of the hepatopancreatic ampulla to relieve blocked biliary or pancreatic ducts.Anastomosis, Surgical: Surgical union or shunt between ducts, tubes or vessels. It may be end-to-end, end-to-side, side-to-end, or side-to-side.Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Pancreas: A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.Kidney Neoplasms: Tumors or cancers of the KIDNEY.Postoperative Complications: Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.Endosonography: Ultrasonography of internal organs using an ultrasound transducer sometimes mounted on a fiberoptic endoscope. In endosonography the transducer converts electronic signals into acoustic pulses or continuous waves and acts also as a receiver to detect reflected pulses from within the organ. An audiovisual-electronic interface converts the detected or processed echo signals, which pass through the electronics of the instrument, into a form that the technologist can evaluate. The procedure should not be confused with ENDOSCOPY which employs a special instrument called an endoscope. The "endo-" of endosonography refers to the examination of tissue within hollow organs, with reference to the usual ultrasonography procedure which is performed externally or transcutaneously.Liver Cirrhosis, Experimental: Experimentally induced chronic injuries to the parenchymal cells in the liver to achieve a model for LIVER CIRRHOSIS.Duodenal Neoplasms: Tumors or cancer of the DUODENUM.Cysts: Any fluid-filled closed cavity or sac that is lined by an EPITHELIUM. Cysts can be of normal, abnormal, non-neoplastic, or neoplastic tissues.Duodenoscopy: Endoscopic examination, therapy or surgery of the luminal surface of the duodenum.Endoscopes: Instruments for the visual examination of interior structures of the body. There are rigid endoscopes and flexible fiberoptic endoscopes for various types of viewing in ENDOSCOPY.Duodenum: The shortest and widest portion of the SMALL INTESTINE adjacent to the PYLORUS of the STOMACH. It is named for having the length equal to about the width of 12 fingers.Cystadenoma, Mucinous: A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.Neoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Hepatic Artery: A branch of the celiac artery that distributes to the stomach, pancreas, duodenum, liver, gallbladder, and greater omentum.Pancreatic Diseases: Pathological processes of the PANCREAS.Taurodeoxycholic Acid: A bile salt formed in the liver by conjugation of deoxycholate with taurine, usually as the sodium salt. It is used as a cholagogue and choleretic, also industrially as a fat emulsifier.Taurochenodeoxycholic Acid: A bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. It acts as detergent to solubilize fats in the small intestine and is itself absorbed. It is used as a cholagogue and choleretic.Gallbladder Diseases: Diseases of the GALLBLADDER. They generally involve the impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, neoplasms, or other diseases.Cystadenocarcinoma: A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)Imino AcidsEnterohepatic Circulation: Recycling through liver by excretion in bile, reabsorption from intestines (INTESTINAL REABSORPTION) into portal circulation, passage back into liver, and re-excretion in bile.Constriction, Pathologic: The condition of an anatomical structure's being constricted beyond normal dimensions.Hepatocytes: The main structural component of the LIVER. They are specialized EPITHELIAL CELLS that are organized into interconnected plates called lobules.Catheterization: Use or insertion of a tubular device into a duct, blood vessel, hollow organ, or body cavity for injecting or withdrawing fluids for diagnostic or therapeutic purposes. It differs from INTUBATION in that the tube here is used to restore or maintain patency in obstructions.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Endoscopy, Digestive System: Endoscopic examination, therapy or surgery of the digestive tract.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Klatskin's Tumor: Adenocarcinoma of the common hepatic duct bifurcation. These tumors are generally small, sharply localized, and seldom metastasizing. G. Klatskin's original review of 13 cases was published in 1965. Once thought to be relatively uncommon, tumors of the bifurcation of the bile duct now appear to comprise more than one-half of all bile duct cancers. (From Holland et al., Cancer Medicine, 3d ed, p1457)Liver Transplantation: The transference of a part of or an entire liver from one human or animal to another.Portal Vein: A short thick vein formed by union of the superior mesenteric vein and the splenic vein.Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Calculi: An abnormal concretion occurring mostly in the urinary and biliary tracts, usually composed of mineral salts. Also called stones.Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.DNA, Neoplasm: DNA present in neoplastic tissue.Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.Organic Anion Transporters, Sodium-Dependent: A subclass of ORGANIC ANION TRANSPORTERS whose transport of organic anions is driven either directly or indirectly by a gradient of sodium ions.Liver Function Tests: Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions.Clonorchiasis: Infection of the biliary passages with CLONORCHIS SINENSIS, also called Opisthorchis sinensis. It may lead to inflammation of the biliary tract, proliferation of biliary epithelium, progressive portal fibrosis, and sometimes bile duct carcinoma. Extension to the liver may lead to fatty changes and cirrhosis. (From Dorland, 27th ed)Lithotripsy, Laser: Fragmentation of CALCULI, notably urinary or biliary, by LASER.Caroli Disease: Congenital cystic dilatation of the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC). It consists of 2 types: simple Caroli disease is characterized by bile duct dilatation (ectasia) alone; and complex Caroli disease is characterized by bile duct dilatation with extensive hepatic fibrosis and portal hypertension (HYPERTENSION, PORTAL). Benign renal tubular ectasia is associated with both types of Caroli disease.Parotid Neoplasms: Tumors or cancer of the PAROTID GLAND.Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.Vitelline Duct: The narrow tube connecting the YOLK SAC with the midgut of the EMBRYO; persistence of all or part of it in post-fetal life produces abnormalities, of which the commonest is MECKEL DIVERTICULUM.Glycocholic Acid: The glycine conjugate of CHOLIC ACID. It acts as a detergent to solubilize fats for absorption and is itself absorbed.Keratin-7: A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.Rats, Inbred F344Time Factors: Elements of limited time intervals, contributing to particular results or situations.Epithelium: One or more layers of EPITHELIAL CELLS, supported by the basal lamina, which covers the inner or outer surfaces of the body.Lung Neoplasms: Tumors or cancer of the LUNG.Cholecystostomy: Establishment of an opening into the gallbladder either for drainage or surgical communication with another part of the digestive tract, usually the duodenum or jejunum.Lacrimal Duct Obstruction: Interference with the secretion of tears by the lacrimal glands. Obstruction of the LACRIMAL SAC or NASOLACRIMAL DUCT causing acute or chronic inflammation of the lacrimal sac (DACRYOCYSTITIS). It is caused also in infants by failure of the nasolacrimal duct to open into the inferior meatus and occurs about the third week of life. In adults occlusion may occur spontaneously or after injury or nasal disease. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p250)Cholesterol: The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.Cholecystography: Radiography of the gallbladder after ingestion of a contrast medium.Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Gastrointestinal Neoplasms: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.Endolymphatic Duct: The part of the membranous labyrinth that traverses the bony vestibular aqueduct and emerges through the bone of posterior cranial fossa (CRANIAL FOSSA, POSTERIOR) where it expands into a blind pouch called the endolymphatic sac.Neoplasms, Connective and Soft Tissue: Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.Rats, Sprague-Dawley: A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.Neoplasms, Plasma Cell: Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Neoplasms, Complex and Mixed: Neoplasms composed of more than one type of neoplastic tissue.Appendiceal Neoplasms: Tumors or cancer of the APPENDIX.Technetium Tc 99m Disofenin: A radiopharmaceutical used extensively in cholescintigraphy for the evaluation of hepatobiliary diseases. (From Int Jrnl Rad Appl Inst 1992;43(9):1061-4)Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Intraoperative Care: Patient care procedures performed during the operation that are ancillary to the actual surgery. It includes monitoring, fluid therapy, medication, transfusion, anesthesia, radiography, and laboratory tests.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Pancreatectomy: Surgical removal of the pancreas. (Dorland, 28th ed)Endocrine Gland Neoplasms: Tumors or cancer of the ENDOCRINE GLANDS.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Sphincter of Oddi Dysfunction: Organic or functional motility disorder involving the SPHINCTER OF ODDI and associated with biliary COLIC. Pathological changes are most often seen in the COMMON BILE DUCT sphincter, and less commonly the PANCREATIC DUCT sphincter.Digestive System Neoplasms: Tumors or cancer of the DIGESTIVE SYSTEM.Cholecystitis, Acute: Acute inflammation of the GALLBLADDER wall. It is characterized by the presence of ABDOMINAL PAIN; FEVER; and LEUKOCYTOSIS. Gallstone obstruction of the CYSTIC DUCT is present in approximately 90% of the cases.Adenoma: A benign epithelial tumor with a glandular organization.Dilatation: The act of dilating.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Cholesterol 7-alpha-Hydroxylase: A membrane-bound cytochrome P450 enzyme that catalyzes the 7-alpha-hydroxylation of CHOLESTEROL in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP7, converts cholesterol to 7-alpha-hydroxycholesterol which is the first and rate-limiting step in the synthesis of BILE ACIDS.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Duodenal Diseases: Pathological conditions in the DUODENUM region of the small intestine (INTESTINE, SMALL).Nose Neoplasms: Tumors or cancer of the NOSE.Neoplasms, Vascular Tissue: Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.Epithelial Cells: Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.Eye Neoplasms: Tumors or cancer of the EYE.Pancreatitis, Chronic: INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)Hamartoma: A focal malformation resembling a neoplasm, composed of an overgrowth of mature cells and tissues that normally occur in the affected area.Dog Diseases: Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.Portal System: A system of vessels in which blood, after passing through one capillary bed, is conveyed through a second set of capillaries before it returns to the systemic circulation. It pertains especially to the hepatic portal system.Fatal Outcome: Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Neoplasms, Radiation-Induced: Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.Cystadenocarcinoma, Mucinous: A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)Cholecystolithiasis: Presence or formation of GALLSTONES in the GALLBLADDER.Adenoma, Villous: An adenoma of the large intestine. It is usually a solitary, sessile, often large, tumor of colonic mucosa composed of mucinous epithelium covering delicate vascular projections. Hypersecretion and malignant changes occur frequently. (Stedman, 25th ed)Fascioliasis: Liver disease caused by infections with parasitic flukes of the genus FASCIOLA, such as FASCIOLA HEPATICA.Testicular Neoplasms: Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.Neoplasms, Muscle Tissue: Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.Neoplasms, Glandular and Epithelial: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.Sweat Gland NeoplasmsNervous System Neoplasms: Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.Intestinal Neoplasms: Tumors or cancer of the INTESTINES.Secretin: A peptide hormone of about 27 amino acids from the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level. (USAN and the USP Dictionary of Drug Names, 1994, p597)Liver Neoplasms, Experimental: Experimentally induced tumors of the LIVER.

Lobar decrease in 99mTc-GSA accumulation in hilar cholangiocarcinoma. (1/1182)

Hilar cholangiocarcinoma can obstruct hepatic ducts and involve the portal veins. Both biliary stasis and decrease in portal venous flow are known to reduce 99mTc-diethylenetriamine pentaacetic acid-galactosyl human serum albumin (GSA) accumulation. The specific relationship between these pathological conditions due to hilar cholangiocarcinomas and 99mTc-GSA accumulation has never been clarified. METHODS: Sixteen patients with hilar cholangiocarcinomas who underwent 99mTc-GSA liver scintigraphy were reviewed. The relationship between significant decrease in 99mTc-GSA accumulation and lobar biliary stasis, or decrease in the portal venous flow, was evaluated. Average counts of region of interest placed in both right and left lobes were compared in the same transaxial SPECT section. Count ratios of right and left lobes were calculated. RESULTS: Significant lobar decrease in 99mTc-GSA accumulation was observed in 6 of the 16 patients. Ipsilateral portal venous stenosis or obstruction was seen in all these 6 patients, whereas ipsilateral portal venous stenosis or obstruction was seen in only 1 of the other 10 patients. Symmetric bile duct dilatation was seen in 13 patients, and asymmetric bile duct dilatation was seen in 3. Lobar decrease in 99mTc-GSA accumulation correlated well with decrease in ipsilateral portal venous flow (P < 0.0005). The count ratio was significantly reduced when unilateral portal venous flow decreased (P < 0.05). CONCLUSION: Using 99mTc-GSA liver scintigraphy, we can predict lobar decrease in ipsilateral portal venous flow and monitor hepatic functional lateralities in patients with hilar cholangiocarcinomas.  (+info)

Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis. (2/1182)

Extrahepatic biliary stenosis can be caused by benign and malignant disorders. In most cases, a tissue diagnosis is needed for optimal management of patients, but the sensitivity of biliary cytology for the diagnosis of a malignancy is relatively low. The additional diagnostic value of K-ras mutational analysis of endobiliary brush cytology was assessed. Endobiliary brush cytology specimens obtained during endoscopic retrograde cholangiopancreaticography were prospectively collected from 312 consecutive patients with extrahepatic biliary stenosis. The results of conventional light microscopic cytology and K-ras codon 12 mutational analysis were compared and evaluated in view of the final diagnosis made by histological examination of the stenotic lesion and/or patient follow-up. The sensitivities of cytology and mutational analysis to detect malignancy were 36 and 42%, respectively. When both tests were combined, the sensitivity increased to 62%. The specificity of cytology was 98%, and the specificity of the mutational analysis and of both tests combined was 89%. Positive predictive values for cytology, mutational analysis, and both tests combined were 98, 92, and 94%, whereas the corresponding negative predictive values were 34, 34, and 44%, respectively. The sensitivity of K-ras mutational analysis was 63% for pancreatic carcinomas compared to 27% for bile duct, gallbladder, and ampullary carcinomas. K-ras mutational analysis can be considered supplementary to conventional light microscopy of endobiliary brush cytology to diagnose patients with malignant extrahepatic biliary stenosis, particularly in the case of pancreatic cancer. The presence of a K-ras codon 12 mutation in endobiliary brush cytology per se supports a clinical suspicion of malignancy, even when the conventional cytology is negative or equivocal.  (+info)

Villous adenoma of the bile ducts: a case report and a review of the reported cases in Korea. (3/1182)

Villous adenomas are benign epithelial lesions with malignant potential which can occur at any site in the gastrointestinal tract. They are usually encountered in the rectum and colon, less frequently in the small bowel and very rarely in the biliary trees. Nine cases of bile duct villous adenomas have been reported in the literature. However, 4 cases of bile duct villous adenomas have been reported in the Korean literature. Recently, we experienced a case of villous adenoma in the common hepatic duct in a 77-year-old man presenting with obstructive jaundice in which preoperative histologic diagnosis of villous adenoma played a critical role in managing this patient. Herein, we present a case report of bile duct villous adenoma and a review of the reported cases in Korea to help define and manage this rare disease entity in the bile ducts. In addition, confusing nomenclature of bile duct adenomas is discussed.  (+info)

Lymph node metastasis in intrahepatic cholangiocarcinoma. (4/1182)

BACKGROUND: Lymph node metastasis is a significant prognostic factor in intrahepatic cholangiocarcinoma. This study was aimed at investigating lymph node metastasis in intrahepatic cholangiocarcinoma and to examine whether the extent of metastasis affects outcomes after surgery. METHODS: From 1980 through 1996, 70 patients with intrahepatic cholangiocarcinoma underwent hepatectomy, with a 50% curative resection rate. Lymph node dissection was performed in 51 patients, and the presence of lymph node metastasis was examined microscopically. The metastatic nodes were divided into groups N1, N2 or N3 using the classification proposed by the Liver Cancer Study Group of Japan. RESULTS: Twenty-three patients had lymph node metastasis. Metastasis was to N1 nodes in 10 patients, to N2 nodes in nine patients and to N3 nodes in four patients. Nineteen patients had metastatic nodes in the hepatoduodenal ligament, which was the most common metastatic site regardless of tumor location. The five-year survival rate in patients with lymph node metastasis (0%) was significantly lower (p < 0.0001) than that in patients without lymph node metastasis (51 %); however, five-year survival rates did not differ between patients with metastases to N1, N2 and N3 nodes. CONCLUSIONS: Lymph nodes in the hepatoduodenal ligament may be sentinel nodes for intrahepatic cholangiocarcinoma, and outcomes after surgery for patients with lymph node metastasis are poor regardless of the sites of nodal metastasis.  (+info)

Promoting effects of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone on rat glandular stomach carcinogenesis initiated with N-methyl-N'-nitro-N-nitrosoguanidine. (5/1182)

The modifying effects of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX), a mutagenic by-product in chlorinated water, on the development of glandular stomach cancers were investigated in Wistar rats. A total of 120 males, 6 weeks of age, were divided into six groups. After initiation with 100 ppm N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) solution and 5% NaCl diet for 8 weeks, 30 rats each in groups 1-3 were given MX in the drinking water at concentrations of 30, 10, or 0 ppm for the following 57 weeks. Ten animals each in groups 4-6 were administered the MX without prior carcinogen exposure. There were no statistical significant differences in final body weights between the groups. The incidences and multiplicities of adenocarcinomas in the glandular stomachs were significantly higher (P < 0.05) in the initiated 30 ppm MX group than those in the MNNG/NaCl group. The incidences of atypical hyperplasias in the glandular stomachs were also significantly increased (P < 0.05 or 0.01) by the MX treatments. With their multiplicity, the effects were clearly dose dependent. Interestingly, the 30 ppm MX alone itself induced atypical hyperplasias in the pylorus, although the incidences and severity were low. Moreover, MX showed a tendency to enhance the development of intrahepatic cholangiocellular tumors and thyroid follicular cell tumors in the MNNG-treated animals. The results of the present study thus indicate that MX exerts promoting effects when given during the postinitiation phase of two-stage glandular stomach carcinogenesis in rats.  (+info)

Problems and perspective in epidemiological study of occupational health hazards in the rubber industry. (6/1182)

An epidemiological analysis of the problems in the study of companies engaged in the manufacture of rubber products in different countries and in different time periods is given. Selected findings on cancer of gallbladder and biliary system, cancer of the lung, and tumors of the central nervous system among rubber workers are presented.  (+info)

Detection of Helicobacter DNA in bile from bile duct diseases. (7/1182)

Several species of Helicobacter colonize the hepatobiliary tract of animals and cause hepatobiliary diseases. The aim of this study is to investigate Helicobacter found in the biliary tract diseases of humans. Thirty-two bile samples (15 from bile duct cancer, 6 from pancreatic head cancer, and 11 from intrahepatic duct stone) were obtained by percutaneous transhepatic biliary drainage. Polymerase chain reaction analysis using Helicobacter specific urease A gene and 16S rRNA primers, bile pH measurement, and Helicobacter culture were performed. Helicobacter DNA was detected in 37.5%, and 31.3% by PCR with ureA gene, and 16S rRNA, respectively. The bile pH was not related to the presence of Helicobacter. The cultures were not successful. In conclusion, Helicobacter can be detected in the bile of patients with bile duct diseases. The possibility of pathogenesis of biliary tract diseases in humans by these organisms will be further investigated.  (+info)

Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. (8/1182)

p73, the first homologue of the tumour suppressor protein p53, was recently discovered on chromosome 1p36 and has been shown to induce apoptosis in a p53-like manner. The present study was performed with the aim of investigating the expression of p53, its new homologue p73 and the occurrence of apoptosis in cholangiocellular carcinoma. Protein levels of p73 were examined in 41 patients with curatively (R0-) resected cholangiocellular carcinomas with an antiserum, raised against a peptide in the N-terminal domain of p73. The incidence of mutations in the p53 gene was analysed by direct sequencing and also immunohistochemically. Apoptotic cell death was assessed using in-situ end-labelling (ISEL) technique in combination with morphological criteria. The results obtained were correlated with patient survival. Immunostaining of p73 protein was detected in 17/41 carcinomas examined (41%). The immunoreactivity was confined to the cell nucleus. In 15/41 patients (37%), mutations of the p53 gene were observed. Eleven out of these 15 patients stained also positive for p73. In contrast, out of 26 patients without any detectable p53 mutation, only six exhibited p73 immunostaining. We failed to observe a correlation between p73 expression or p53 and apoptosis within a given tumour. Survival analysis including the parameters stage and grade of disease, p73 and p53, and also apoptosis, showed that tumour stage and grade as well as p53 and p73 were significantly related to prognosis. In Cox regression survival analysis, however, only extent of primary tumour and lymph node status had an independent prognostic impact. Our results with a high prevalence of p73 within tumours harbouring mutated p53 gene suggest that p73 could compensate for p53 function. We failed to establish p73 or p53 as independent prognostic factors in cholangiocellular carcinoma of the liver.  (+info)

BACKGROUND/AIMS Mucin-hypersecreting bile duct tumor is rare, and has an unusual histologic characteristic of having various degrees of cellular atypia ranging from dysplasia to invasive carcinoma in the same specimen. To gain insight into the role of p16, p14 and p53 in the carcinogenic process of bile duct tumor, we analyzed the expression status of these proteins in mucin-hypersecreting bile duct tumor. METHODS Immunohistochemical staining of p16, p14 and p53 were performed in 34 paraffin embedded tissues obtained from 22 patients of mucin-hypersecreting bile duct tumor. RESULTS Thirty-four specimens were categorized into low-grade dysplasia (9), high-grade dysplasia (4), carcinoma in situ (CIS, 11) and invasive carcinoma (10) based on the degree of cytologic and structural atypia. p53 overexpressions were found in 6 (17.6%, 3 in CIS, 3 in invasive carcinoma) and more frequently observed in the advanced histologic stages (p|0.05). Loss of p16 staining was found only in 2 (6%) of low-grade
Northeastern Thailand has the highest levels bile duct cancer in the world. The determination that plasma IL-6 levels are associated with bile duct fibrosis (a precursor state to bile duct cancer) and early bile duct cancer were done by examining participants in the Khon Kaen Cholangiocarcinoma Cohort, the largest cancer cohort of its type in the world, and an NIH sponsored project in collaboration with George Washington University and Khon Kaen University. In this study, researchers visited nearly 4,000 individuals resident in rural areas of Thailand, where the parasite is endemic to conduct ultrasound studies to detect advanced bile duct fibrosis and early bile duct cancer and then link the ultrasound results with levels of plasma IL-6. This research was done in collaboration with Drs. Banchob Sripa, Bandit Thinkhamrop, Eimorn Mairiang, and Thewarach Laha from the Khon Kaen University School of Medicine and School of Public Health. ...
Cancer of the bile duct (also called cholangiocarcinoma) is extremely rare. The true incidence of bile duct cancer is unknown, however, because establishing an accurate diagnosis is difficult. Traditionally, bile duct tumors located within the liver have been classified with hepatocellular carcinoma as primary liver...
Find the best bile duct cancer doctors in Bangalore. Get guidance from medical experts to select bile duct cancer specialist in Bangalore from trusted hospitals - credihealth.com
Confocal endomicroscopy (CholangioFlex) was performed at the suspected area. The video will record the images with Cellvizio program recorder.. 6.Brush cytology was performed 7.Record the duration and complication of the procedure 8.Send the tissues to one clinically-blinded GI pathologist for pathological diagnosis and FISH test 9.Compare the pathology and FISH report and endoscopic finding 10.Report the result According to Miami-criteria 2009, the Criteria for malignant biliary stricture from CholangioFlex are one of the followings;. ...
For cases of inoperable bile duct carcinoma, we perform intraluminal irradiation using an 192iridium wire following endoprostheses implantation. However, the effectiveness of this procedure is uncertain, and may lead to decreased patient quality of life in some cases. Therefore, we obtained samples of bile duct carcinoma either by percutaneous transhepatic cholangioscope (PTCS) or by surgery, and studied whether expression levels of Ki-67 and p53 in these tissues could predict the effectiveness of radiotherapy (RT). Immunohistochemistry was used to determine the expression of p53 and Ki-67 in 40 resected and 18 biopsy specimens. All biopsy specimens were stage IVA according to UICC classification. Labeling indices were calculated as percentage of positively stained tumor cell nuclei of total tumor cells counted. Samples were divided into two groups according to labeling index (LI). In the resected specimens, Ki-67 LI was significantly higher in cases positive for lymphatic invasion than in ...
Bile duct cancer starts in the cells of a bile duct. Learn about symptoms, diagnosis, treatment and risks in our guide to bile duct cancer.
Linear 125 I Seeds Implantation Combined with Biliary Stent Insertion is an emerging effective treatment for bile duct cancer patients with obstructive jaundice, which can simultaneously treat biliary obstruction and bile duct tumors, bringing new hop
Our previous studies have demonstrated that up-regulated lung cancer 10 (URLC10) has been identified as a new target of tumor associated antigen using cDNA microarray technique combined with the expression profiles of normal and cancer tissues. We have also found that 100% of tissue samples from bile duct cancer express URLC10. We have determined the HLA-A*2402 and HLA-A*0201 restricted epitope peptides derived from URLC10.These epitope peptides have shown to induce specific Cytotoxic T Lymphocytes (CTL). Furthermore, 60% and 20% of Japanese population have HLA-A*2402 and HLA-A*0201, respectively. Therefore, these peptides are suitable for clinical trial. On the other hand, gemcitabine is a drug approved against bile duct cancer. Recent studies has reported that gemcitabine has an additional ability to improve immune response. From these results, synergistic effect between vaccine therapy and chemotherapy using gemcitabine will be expected.. In this clinical trial, we evaluate the safety, ...
There are several bile duct cancer treatment and preventive procedures to administer to patients of bile duct cancer. Treatments would vary depending on th
Cholangiocellular Carcinoma in Dogs Bile duct carcinoma is a malignant cancer that typically arises from the the epithelia, the cellular lining of the hepatic (
Bile duct cancer symptoms include jaundice and abdominal pain. Turn to the expert gastroenterologists at Johns Hopkins for accurate diagnosis and personalized treatment.
Looking for simple explanations to difficult medical terms that tend to puzzle you? This glossary can help you to easily understand medical terms related to the article on Bile Duct Cancer
Jaundice. This is the yellowing of the whites of the eyes and skin. Its caused by a buildup of bilirubin in the blood. Bilirubin is a yellow-brown substance in bile. The liver makes bile. Bile travels from the liver through the bile ducts the intestine. Bile digests or breaks down fats from food in the intestine. If the bile ducts are blocked by a tumor or scarring, bile backs up. Jaundice is the most common symptom of bile duct cancer outside the liver (extrahepatic).. ...
Bile duct cancer describes a type of cancer that forms in the bile ducts (slender tubes) that carry the digestive fluid bile through the liver. Get treatment now!
Bile duct cancer (also called cholangiocarcinoma) can occur in the bile ducts in the liver (intrahepatic) or outside the liver (perihilar or distal extrahepatic). Learn about the types of bile duct cancer, risk factors, clinical features, staging, and treatment for bile duct cancer in this expert-reviewed summary.
Regular physical challenges remain, causing pain, queasy stomach treating bile duct cancer after gallbladder infections of the gallbladder. These remedies, you could be because I felt nauseous and pain in gallbladder not confirm gallstones. PMID 11930198 Myers RP, Shaffer EA, Beck PL 2002. Just beneath your spot on the liver qi deficiency liver or bile pigment crystals and become too large numbers. Shiftig of worn-out red blood pancreatic cancer prognosis kidney disease cells, into the doc about it, but eating certain herbs that work on your health, many experts highly recommend this. These hardened deposits that results in problems after gallbladder removal gallstones the gallbladder is an extensive buildup of scar tissue pancreatic cancer prognosis kidney disease from older surgery recovery. Other symptoms include fever, drainage from $6, 000. The adoption of the gallbladder in order to prevent gallstones naturally and financially saturated fats. Once the pellets continue cirrhosis of ...
liver disease facts mexico Kid clear capsule is there is a risk of gallbladder removal was done in order to cure and delivers excellent results. Gallstones can be caused by some natural health problems once they become large and clinical interventions in the gallbladder pain and risks that should be taken. Therefore, it is an important internal organ illnesses. As a result of which uses more cholesterol is impossible. Try these foods: eggs, dairy, are still over a 20-year period. These are usually suggested according to the hospital for two more weeks, I have done long ago. It is most metastasis of treatment for fatty liver disease in alcoholics bile duct cancer likely to suffer from these as compared to men. To follow the guidelines for instance instead of tasty and three-dimensional visualization, enhanced dexterity, greater precision, enhanced maneuverability and try to dissolve and pass your gallbladder. The bile in the abdomen that showed raised antibodies to gluten/gliadin, among other ...
Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer.
Chemotherapy (chemo) is a treatment of cancer-killing drugs used to kill bile duct cancer cells. Learn more about chemotherapy here.
Hi,. My mom was just diagnosed with Bile Duct Cancer.. I am in departed need of anyone who has dealt with this type of cancer, or any ones family members who had this. I also would love to hear from people who has beat this type of cancer... this has been a world-wind we never ever expected this to happen; especially in November we was told NO-Cancer!! My mom is my life; we are best friends she lives not even a mile from me. I am so hurt, mad & even angry. I have never ever felt so alone in my LIFE... I will be by my mothers side every-step of the way... I want any suggestions on how to cope with all feelings I am felling. Please help!!!! ...
Bile duct cancer diagnosis (costs for program #33463) ✔ Sana Hospital Duisburg ✔ Department of Internal Medicine II (Gastroenterology and Hepatology) ✔ BookingHealth.com
You cant change the fact that you had bile duct cancer, but you can change how you live the rest of your life by making healthy lifestyle choices.
Bile duct carcinoma is a malignant cancer that typically arises from the the epithelia, the cellular lining of the hepatic (liver) bile ducts.
A. AIH - Autoimmune Hepatitis. ALP - Alkaline Phosphatase (ALP). ALT - Alanine Aminotransferase (sometimes called SGPT). AST - Aspartate Aminotransferase (sometimes called SGOT). Asymptomatic - displaying no symptoms. B. Bacterial cholangitis - infection in the bile ducts. Bile ducts - the passages that carry bile from the liver to the intestines. BMD - bone mass density. C. CCA - cholangiocarcinoma (bile duct cancer). CD - Crohns Disease. Cholangiocarcinoma - bile duct cancer. Choledocholithiasis - biliary stones. Colonoscopy - test to examine the colon and rectum. D. DEXA - bone density scan. E. ERCP - Endoscopic retrograde cholangiopancreatogram. Extrahepatic - outside the liver. F. Fatigue - debilitating tiredness. G. GGT - Gamma-Glutamyl Transferase. H. HCC - hepatocellular carcinoma. HE - hepatic encephalopathy. I. IAC - Immunoglobulin G4 (IgG4) Associated Cholangitis. IBD - Inflammatory Bowel Disease. IgG4 - Immunoglobulin G4. Intrahepatic - within the liver. L. LFT - Liver function ...
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. ...
The superior mesenteric, splenic and portal vein are shown in relation to the pancreas and superior mesenteric artery. The first branches arising from the anterior surfaces of SMA and SMV are the middle colic vessels. Note the small venous branches from the head draining into the right side of the SMV/portal veins, and the multiple small branches from the body of the pancreas draining into the anterior surface of the splenic vein ...
belly buttons using the beet. She was the formation is the best remedies for gallbladder. Bile is a common place surgery every surgery and only you can do for you as it used to reduce inflammation of the gallbladder removal, indigestion symptoms with back pain the authors concluded that is attached to the military may emerge. This caused by feelings and feeling pretty lousy! The gallbladder detox diet containing fats, the gallstones have been taught at medical schools. Recommended procedure of removing bile duct cancer survival rate natural remedies for gallstones removal gallstones without the next 10 years after the procedure each year more than 10 cm sac that is because if you have a high fat and lean cuts. Thats why bile duct cancer survival rate mates and loved ones, along with increasing. It is when the organ is extremely popular for people with cancer. One should also be experiencing are similar to a variety of procedure each year more than 15-20 years, you should have felt sick after ...
Tina, dont give up even if you think the doctors giving up. My CT scan came back six weeks ago after my treatments, not looking good. I went to the gastroentrologist that had put in the stent and he did not want to answer any of my questions. He answered them by telling me to ask the oncologist. I asked about making another follow-up appointment and he said he didnt think that would be necessary. What a blow that was! I went to the oncologist and after I got a copy of the report, I could see that it did not look good, I called and wanted to ask some questions and he said we would talk about it in a month after I have another CT scan. Another blow! I was not going to sit around, so I made an appointment with another oncologist and she went over my CT scan and explained that it did not look that bad. The new spot on the liver could be a cyst and the fluid around the gallbladder did not mean it was cancer and the fluid would probably go away. I did have another CT scan just before Christmas and ...
In bile duct cancer, the cancerous cells may release certain chemicals that can be detected using blood tests. These are known as tumour markers.. But tumour markers can also be caused by other conditions, so this test cant be used to say for certain whether or not you have bile duct cancer.. ...
Purpose: MEK inhibition has clinical activity against biliary cancers, and might therefore be successfully combined with gemcitabine; one of the most active chemotherapy agents for these cancers. As gemcitabine is active in S-phase, and the ERK pathway has a major role driving cell cycle progression, concurrent use of a MEK inhibitor could potentially antagonize the effect of gemcitabine. We therefore tested the sequence dependence of the combination of gemcitabine and the MEK inhibitor AZD6244 using a series of biliary cancer models. Experimental Design: Primary xenografts were established from patients with gallbladder and distal bile duct cancer, and grown in SCID mice at the subcutaneous site. Plasma and tumor drug levels, and the time course for recovery of ERK signaling and S-phase were measured in tumor-bearing mice treated for 48hr with AZD6244 and then monitored for 48hr off treatment. Based on these results, two different treatment schedules combining AZD6244 with gemcitabine were ...
Aim: To review the world literature on the histogenesis, diagnosis and management of Bellini duct carcinoma and to suggest a possible clinical algorithm to assist in their identification and appropria
2008 is soon a wrap, and its time to update my list of the different diagnostic and cancer treatment videos Ive filmed for the www.oncolex.no project over the last three and a half years. The project is almost completed, but I still have some filming related to liver-, pancreatic-, gall bladder- and bile duct cancer…
Slug is an E-cadherin repressor and a suppressor of PUMA (p53 upregulated modulator of apoptosis) and it has recently been demonstrated that Slug plays an important role in controlling apoptosis. In this study, we examined whether Slugs ability to silence expression suppresses the growth of cholangiocarcinoma cells and/or sensitizes cholangiocarcinoma cells to chemotherapeutic agents through induction of apoptosis. We targeted the Slug gene using siRNA (Slug siRNA) via full Slug cDNA plasmid (Slug cDNA) transfection of cholangiocarcinoma cells. Slug siRNA, cisplatin, or Slug siRNA in combination with cisplatin, were used to treat cholangiocarcinoma cells in vitro. Western blot was used to detect the expression of Slug, PUMA, and E-cadherin protein. TUNEL, Annexin V Staining, and cell cycle analysis were used to detect apoptosis. A nude mice subcutaneous xenograft model of QBC939 cells was used to assess the effect of Slug silencing and/or cisplatin on tumor growth. Immunohistochemical staining was used
Tumor staging of extrahepatic bile duct (EBD) carcinoma is problematic for a number of reasons, including definitional problems with the current T classification of the American Joint Committee on Cancer staging system and the common occurrence of severe desmoplastic stromal reaction around the adva
Survival statistics for extrahepatic bile duct cancer are very general estimates and must be interpreted very carefully. Because these statistics are based on the experience of groups of people, they cannot be used to predict a particular persons chances of survival.
TY - JOUR. T1 - Carcinoma of the extrahepatic bile ducts. AU - Wei, T. C.. AU - Wei, P. L.. AU - Yu, S. C.. AU - Lee, P. H.. AU - Hsu, S. C.. PY - 1995. Y1 - 1995. N2 - Fifty-two patients with carcinoma of the extrahepatic bile ducts were reviewed. There were 28 men and 24 women whose ages ranged from 31 to 78 years, with a mean age of 58 years. Symptoms, signs and laboratory results were primarily the result of bile duct obstruction. The most valuable diagnostic procedures were percutaneous transhepatic cholangiography and endoscopic retrograde cholangiopancreatography. In 28 patients the tumor was located in the upper, 9 in the middle and 12 in the lower common bile duct. In the other three patients the tumor was diffuse. The resectability rate was 21.2% (11/52). Of the remaining patients, 10 (19.2%) had T-tube drainage, 5 (9.6%) had biliary digestive anastomosis, 18 (34.6%) had percutaneous transhepatic biliary drainage and 8 (15.4%) had biopsy only. The histologic diagnosis was sclerosing in ...
[504 Pages Report] Check for Discount on Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016 report by Global Markets Direct. Global Markets Directs, Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review,...
Background and Aims: It is a challenge to collect samples from bile duct strictures to diagnose patients with cholangiocarcinoma. We investigated the utility of the Spyglass Spyscope, a single-operator endoscope that is used to perform cholangiopancreatoscopy, to identify extrahepatic cholangiocarcinoma in patients who were not diagnosed with this disorder by endoscopic retrograde cholangiopancreatography (ERCP) cytology or endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) analyses. Methods: We conducted a retrospective analysis of data from 30 patients (median age, 67 years; 67percent male) with indeterminate extrahepatic biliary strictures who were ultimately diagnosed with cholangiocarcinoma but had inconclusive results from initial biliary ductal brush cytology and EUS-FNA analyses. Patients then underwent cholangioscopy by using the Spyglass Spyscope and intraductal biopsy analysis. None of the patients had a definitive mass in abdominal imaging or EUS analyses. Results: The ...
Cholangiocarcinoma, also known as bile duct cancer, is often treated the same way as hepatocellular carcinoma, the most common form of primary liver cancer that develops in the main type of liver cell.
Learn more about Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®) (Patients) from the National Cancer Institute at Siteman Cancer Center.
Learn about bile duct cancer (cholangiocarcinoma) from the Cleveland Clinic, including information on treatment options, stages & more.
Cholangiocarcinoma is a malignant tumor that originates from the bile duct epithelium (Roberts et al., 1997). Based on its anatomical location in the biliary tree, cholangiocarcinoma is conventionally classified by the World Health Organization as an intrahepatic (ICC) or extrahepatic cholangiocarcinoma (ECC) (Bosman et al., 2010; Patel, 2011). ICC and ECC are biologically distinct, and therefore manifest substantial differences in terms of incidence, mortality, and risk factors (Cardinale et al., 2010). Cholangiocarcinoma has a poor prognosis because it is notoriously difficult to diagnose due to its late clinical presentation, and is refractory to conventional chemotherapy and radiation therapy (Blechacz and Gores, 2008; Blechacz et al., 2011; Khan et al., 2012). Gemcitabine and cisplatin has become the standard regimen for patients with advanced or metastatic cholangiocarcinoma (Ramirez-Merino et al., 2013; Valle et al., 2010). However, response to the combination chemotherapy in ...
Bile duct cancer. Coloured angiogram (X-ray) of a patients common bile duct (dark red, centre right) that has been blocked by cancer. The cancer (not seen) has caused a narrowing, or stricture, of the duct. A stent (fine mesh tube, lower frame) has been permanently inserted into the duct to correct the stricture. A tube (catheter) inside the stent will be removed when fluid has drained from the duct. Bile fluid, secreted by the liver cells, emulsifies ingested fats. It drains into the small intestine through the common bile duct when food enters the intestine. A contrast medium injected into the duct makes it visible on X-ray. - Stock Image M134/0418
Bile duct strictures are either benign or malignant. Malignant strictures are usually short and irregular with shouldering margins, as in this case. This suggests the diagnosis of hilar cholangiocarcinoma (Klatskin tumor), but there is no pathol...
Matthew Weiss, MD, FACS, specializes in surgery for pancreatic and liver cancer, as well as benign hepatopancreatobiliary diseases, including cystic lesions of the pancreas. In addition to performing the Whipple procedure, he has particular expertise in minimally invasive pancreatic resections. Dr. Weiss clinical interests also include colorectal metastases to the liver, hepatocellular carcinomas, intrahepatic cholangiocarcinomas, bile duct cancers (Klatskin tumors), intraductal papillary mucinous neoplasms of the pancreas, neuroendocrine tumors, and gallbladder cancers. ...
p16Ink4 and p15Ink4B are cyclin-dependent kinase 4 inhibitors and link to the regulation of cell cycle in mammalian cells. The genes encoding these inhibitors are located at 9p21, which is a frequent site of allelic loss in various types of tumors. Twenty-five primary biliary tract cancers were examined for somatic mutations in p16Ink4/CDKN2, p15Ink4B/MTS2, p53, and K-ras genes and allelic loss of 9p21 by microsatellite analysis. Four biliary tract cancer cell lines were analyzed for homozygous deletions and point mutations. We found frequent homozygous deletions in p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in the biliary tract cancer cell lines. Each cancer cell line had alteration of either p16Ink4/CDKN2, p15Ink4B/MTS2, or p53 genes. In primary tumors, 16 of 25 (64%) biliary tract cancers had point mutations in the p16Ink4/CDKN2 gene. These include 14 missense and 2 silent mutations. The frequency of mutations in gall bladder cancer and hilar bile duct cancer were 80% (8 of 10) and 63% (5 of 8), ...
Biophys. Acta. 1573, 388-393. , Muller, W. , and Dennis, J. W. (2000). Suppression of tumor growth and metastasis in Mgat5‐deficient mice. Nat. Med. 6, 306-312. Haltiwanger, R. , and Lowe, J. B. (2004). Role of glycosylation in development. Annu. Rev. Biochem. 73, 491-537. , and Taniguchi, N. (1996). Transcriptional regulation of the N‐acetylglucosaminyltransferase V gene in human bile duct carcinoma cells (HuCC‐T1) is mediated by Ets‐1. J. Biol. Chem. 271, 26706-26712. Lowe, J. , and Marth, J. 6, 306-312. Haltiwanger, R. , and Lowe, J. B. (2004). Role of glycosylation in development. Annu. Rev. Biochem. 73, 491-537. , and Taniguchi, N. (1996). Transcriptional regulation of the N‐acetylglucosaminyltransferase V gene in human bile duct carcinoma cells (HuCC‐T1) is mediated by Ets‐1. J. Biol. Chem. 271, 26706-26712. Lowe, J. , and Marth, J. D. (2003). A genetic approach to Mammalian glycan function. Annu. Rev. Biochem. 72, 643-691. , Hoodless, P. , and Wrana, J. L. (1996). MADR2 is a ...
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patients clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician ...
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patients clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician ...
Rare Cancer News & Clinical Trials » Trial - Bile Duct Cancer » A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic ...
Evidence on the association between physical activity and risk of hepatobiliary cancers is inconclusive. We examined this association in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC). We identified 275 hepatocellular carcinoma (HCC) cases, 93 intrahepatic bile duct cancers (IHBCs), and 164 non-gallbladder extrahepatic bile duct cancers (NGBCs) among 467,336 EPIC participants (median follow-up 14.9 years). We estimated cause-specific hazard ratios (HRs) for total physical activity and vigorous physical activity and performed mediation analysis and secondary analyses to assess robustness to confounding (e.g. due to hepatitis virus infection). In the EPIC cohort, the multivariable-adjusted HR of HCC was 0.55 (95% CI 0.38-0.80) comparing active and inactive individuals. Regarding vigorous physical activity, for those reporting ,2 hours/week compared to those with no vigorous activity, the HR for HCC was 0.50 (95% CI 0.33-0.76). Estimates were similar in sensitivity ...
Evidence on the association between physical activity and risk of hepatobiliary cancers is inconclusive. We examined this association in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC). We identified 275 hepatocellular carcinoma (HCC) cases, 93 intrahepatic bile duct cancers (IHBCs), and 164 non-gallbladder extrahepatic bile duct cancers (NGBCs) among 467,336 EPIC participants (median follow-up 14.9 years). We estimated cause-specific hazard ratios (HRs) for total physical activity and vigorous physical activity and performed mediation analysis and secondary analyses to assess robustness to confounding (e.g. due to hepatitis virus infection). In the EPIC cohort, the multivariable-adjusted HR of HCC was 0.55 (95% CI 0.38-0.80) comparing active and inactive individuals. Regarding vigorous physical activity, for those reporting ,2 hours/week compared to those with no vigorous activity, the HR for HCC was 0.50 (95% CI 0.33-0.76). Estimates were similar in sensitivity ...
Find the best cholangiocarcinoma doctors in Kolkata. Get guidance from medical experts to select cholangiocarcinoma specialist in Kolkata from trusted hospitals - credihealth.com
Cholangiocarcinomas (bile duct cancers) arise from the epithelial cells of the bile ducts. Although they are rare in the United States, these cancers are highly lethal because most are locally advanced at presentation. (See.)The clinical manifestatio
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
We value your privacy. Your user session will expire in 2 minutes. To stay logged in, please refresh the page or, if you are ...
My mother died of Cholangiocarcinoma. This is a very uncommon cancer of the bile duct. I have since that day, started this site. Not until today did I look up Cholangiocarcinoma specifically. What I just found astounds me... Was Mom taking a trial drug? A drug that wasnt even approved by the FDA? She…
Safety Profile. The most common treatment-related adverse events among all patients who received ivosidenib (including after crossover) included nausea (32.1%), diarrhea (28.8%), fatigue (23.7%), cough (19.2%), abdominal pain (18.6%), ascites (18.6%), decreased appetite (17.3%), anemia (16.0%), and vomiting (16.0%). Grade 3 adverse events were reported in 46% of patients treated with ivosidenib compared to 36% of patients treated with placebo. More of the placebo arm (8.5% vs. 5.8%) discontinued treatment due to toxicity, and ivosidenib was associated with better physical and emotional functioning on quality-of-life measures.. "These pivotal data demonstrate the clinical relevance and benefit of ivosidenib in patients with IDH1-mutated cholangiocarcinoma and establish the role for genomic testing in this rare cancer with a high unmet need," Dr. Abou-Alfa said. All patients with cholangiocarcinoma should be tested for the IDH1 mutation, he maintained.. FIGHT-202. FIGHT-202 was a global, ...
A rare disease in which malignant (cancer) cells form in the part of bile duct that is outside the liver. Also known as Cholangiocarcinoma.
As part of the digestive system, bile ducts help digest food properly. If cancer spreads to the liver, the chemical balance of the body will be disturbed.
This work was supported by National Institutes of Health (NIH; Bethesda, MD) grants NIH DK59427 (to G.J.G.), NIH R01 CA 83650, R01 CA 39225 (to A.E.S.), the optical microscopy, clinical, and genetics core of NIH DK84567, and the Mayo Foundation. C.D.F. is a German Research Foundation fellow (Deutsche Forschungsgemeinschaft; grant FI 1630/1-1). ...
Its important to know which medicines youre taking. Write your medicines down, ask your healthcare team how they work, and what side effects they might have. Keep a written diary of your treatment schedule and any signs or symptoms you have.. Talk with your healthcare providers about what signs to look for, and when to call them. Chemotherapy can make you more likely to get infections.. It may be helpful to keep a diary of your side effects. Write down physical, thinking, and emotional changes. A written list will make it easier for you to remember your questions when you go to your appointments. It will also make it easier for you to work with your medical team to make a plan to manage your side effects.. ...
Am I pooping enough? Why is my poop green?" Seemingly silly questions like these are, in fact, important to understanding your body. The bowel movement chart below will help you decode your stool and discover helpful insights into your health. Keep in mind that everyones body is different and only a medical professional can evaluate your individual symptoms and observations.. ...
In PSC, a key feature is the development of scar tissue (fibrosis) that predominantly affects the medium- to large-sized bile ducts within and outside the liver. This can most often be identified with a special MRI scan (called MRCP), although occasionally a liver biopsy is needed for confirmation. PSC can affect men and women at any age, although it is commonly diagnosed in the fourth decade of life, most often in the presence of inflammatory bowel disease (IBD) [2].. Close monitoring of PSC patients is vital. Because of the increased colon cancer risk in PSC patients with ulcerative colitis, annual colonoscopies are advised. Moreover, the presence of colitis is associated with a greater risk of liver disease progression and bile duct cancer (cholangiocarcinoma) [4]. Individuals with PSC can occasionally develop abdominal pain and fever, which may suggest infection of the bile ducts called cholangitis. Although the latter can be treated with antibiotics, no currently known treatment has been ...
Hello all,. My father (aged 57) was recently diagnosed with cholangiocarcinoma and they are not sure if it is operable. We have been offered a clinical trial regarding nab-paclitaxel, gemcitabine, and cisplatin. Have any of you had any experiences using this cocktail? Or know any information regarding it? We would love to know your thoughts/opinions before we decide to move forward.. ...
Learn about the TNM System, a standard system for describing the extent of a cancers growth in cases of cancer such as cholangiocarcinoma.
The Cholangiocarcinoma Foundation has created this important education campaign for the benefit of its constituency and the broader community. To that end, the Foundation encourages broad dissemination of these resources and materials. Promotion of the Mutations Matter campaign by third parties does not indicate endorsement by the Foundation of those third parties or any of their programs, activities or products.. ...
Learn more about Cholangiocarcinoma at Reston Hospital Center DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Learn more about Cholangiocarcinoma at Reston Hospital Center DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Magnetic resonance imaging, or MRI, uses a magnet to examine the inside of your body, useful for diagnosing conditions like cholangiocarcinoma.
Liver cancer. Gross clinical specimen of a sectioned human liver with a malignant (cancerous) tumour (neoplasm) of the bile duct. This is a rare cancer known as cholangiocarcinoma or cholangioma, found most often in patients from certain parts of Africa and Asia. Its cause is unknown. Symptoms of cholangiocarcinoma include jaundice & weight loss. - Stock Image M131/0431
Memorial Sloan Kettering medical oncologist James Harding specializes in caring for people with liver cancer, gallbladder cancer, and bile duct cancer, as well as other gastrointestinal cancers.
A multi-disciplanary team of specialists treat liver, pancreas and bile duct cancer at Froedtert & the Medical College of Wisconsin.
Teaching Files with CT Medical Imaging and case studies on Anatomical Regions including Adrenal, Colon, Cardiac, Stomach, Pediatric, Spleen, Vascular, Kidney, Small Bowel, Liver, Chest | CTisus
Use SelfDecode to get personalized health recommendations based on your genes. Get started today with an existing DNA file or order a SelfDecode DNA kit!
Case Scenario Mrs. J., is a woman in her 40s with cholangiocarcinoma*, which is advanced. She has been admitted to the hospital with a new onset of back pain, nausea and vomiting. She has already undergone surgery and a course.
TY - JOUR. T1 - Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma. T2 - Outcome after liver transplantation. AU - Maganty, Kishore. AU - Levi, David. AU - Moon, Jang. AU - Bejarano, Pablo A.. AU - Arosemena, Leopoldo. AU - Tzakis, Andreas. AU - Martin, Paul. PY - 2010/12/1. Y1 - 2010/12/1. N2 - Background: Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma is a rare hepatobiliary malignancy incorporating components derived from both hepatocyte and intrahepatic bile duct epithelium. The natural history, treatment, and prognosis of this distinct cancer differ from hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) and are not completely understood. There is considerable controversy about the classification, treatment, and survival, which in turn is related to the rarity of the condition. Treatment options include surgical resection and the prognosis is believed to be better than CC but worse than HCC alone. Methods: We report a single-center liver ...
TY - JOUR. T1 - Scrape biopsy of malignant biliary stricture through percutaneous transhepatic biliary drainage tracts. AU - Yip, C. K Y. AU - Leung, Joseph. AU - Chan, M. K M. AU - Metreweli, C.. PY - 1989. Y1 - 1989. N2 - We describe a new technique for scrape biopsy of bile-duct strictures that can be done at the same time as percutaneous transhepatic biliary drainage.. AB - We describe a new technique for scrape biopsy of bile-duct strictures that can be done at the same time as percutaneous transhepatic biliary drainage.. UR - http://www.scopus.com/inward/record.url?scp=0024507320&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0024507320&partnerID=8YFLogxK. M3 - Article. C2 - 2644776. AN - SCOPUS:0024507320. VL - 152. SP - 529. EP - 530. JO - American Journal of Roentgenology. JF - American Journal of Roentgenology. SN - 0361-803X. IS - 3. ER - ...
TY - JOUR. T1 - The impact of portal vein resection on outcomes for hilar cholangiocarcinoma. T2 - A multi-institutional analysis of 305 cases. AU - De Jong, Mechteld C.. AU - Marques, Hugo. AU - Clary, Bryan M.. AU - Bauer, Todd W.. AU - Marsh, J. Wallis. AU - Ribero, Dario. AU - Majno, Pietro. AU - Hatzaras, Ioannis. AU - Walters, Dustin M.. AU - Barbas, Andrew S.. AU - Mega, Raquel. AU - Schulick, Richard D.. AU - Choti, Michael A.. AU - Geller, David A.. AU - Barroso, Eduardo. AU - Mentha, Gilles. AU - Capussotti, Lorenzo. AU - Pawlik, Timothy M.. PY - 2012/10/1. Y1 - 2012/10/1. N2 - BACKGROUND. Surgical strategy for hilar cholangiocarcinoma often includes hepatectomy, but the role of portal vein resection (PVR) remains controversial. In this study, the authors sought to identify factors associated with outcome after surgical management of hilar cholangiocarcinoma and examined the impact of PVR on survival. METHODS: Three hundred five patients who underwent curative-intent surgery for hilar ...
The original observations of this study relate to inflammation, NO production, DNA damage, and inhibition of DNA repair as related mechanisms for the development and/or progression of cholangiocarcinoma. Our results directly demonstrate the following: (a) human cholangiocarcinomas express the iNOS protein; (b) proinflammatory cytokines stimulate iNOS message and protein expression and the production of NO in cholangiocarcinoma cell lines; (c) the magnitude of NO produced is sufficient to cause single-stranded, double-stranded, and oxidative DNA lesions in the malignant cell lines; and (d) stimulated NO generation is associated with impaired global DNA repair activity in the cholangiocarcinoma cell lines. These data suggest that NO generated in response to inflammation may initiate malignant transformation of biliary epithelia and/or promote progression of established cholangiocarcinoma. Each of these observations is discussed in greater detail below.. iNOS expression with NO generation has been ...
Lymphoepithelioma-like carcinoma (LELC) of the liver is extremely rare. To our knowledge, only 16 cases of pure LELC or LELC with ordinary adenocarcinoma arising in the hepatobiliary tract have been reported in the English literature.1-7 Most of these tumours (68%, 11/16) were positive for Epstein-Barr virus (EBV) by EBV-encoded small non-polyadenylated RNA (EBER-1) in situ hybridisation.1-6 However, association of intrahepatic cholangiocarcinoma bearing an intense lymphoplasmacytic infiltration with EBV infection has not been reported. We were the first to present two cases of intrahepatic cholangiocarcinoma with dense lymphoplasmacytic infiltration from Southern China, an area that is well known for and has a high-incidence of nasopharyngeal carcinoma, showing EBV infection, but one case of LELC was associated with EBV infection as well. ...
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage ...
Forest plot of extrahepatic cholangiocarcinoma risk associated with HCV infection. The pooled risk estimate was 1.75 (95% CI, 1.00 to 3.051).
Surgical resection remains the mainstay of curative treatment for intrahepatic cholangiocarcinoma (ICC). Prognosis after surgery is unsatisfactory despite improvements in treatment and post-operative clinical management. Despite developments in the molecular profiling of ICC, the preoperative prediction of prognosis remains a challenge. This study aimed to identify clinical prognostic indicators by investigating the molecular profiles of ICC and evaluating the preoperative imaging data of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET). A retrospective analysis was performed on 50 consecutive patients with ICC who underwent curative hepatectomy after 18F-FDG-PET examination. To evaluate the molecular profiles of ICC, KRAS mutation status was assessed in resected specimens. For the assessment of glucose uptake, we observed the expression of glucose transporter-1 (GLUT-1) by immunohistochemistry. The data of 18F-FDG-PET were re-evaluated as follows: maximum standardized uptake value,
Few studies have evaluated the risk of cancers other than hepatocellular carcinoma associated with hepatitis B virus (HBV) infection. This study aimed to estimate incidence rates of intrahepatic cholangiocarcinoma (ICC) and non-Hodgkin lymphoma (NHL) and its major subtypes in a nationwide cohort of parous women and to assess their associations with chronic HBV infection. We conducted a cohort study including 1,782,401 pregnant Taiwanese women whose HBV serostatus was obtained from the National Hepatitis B Vaccination Registry. Newly diagnosed ICCs and NHLs were ascertained through data linkage with the National Cancer Registry. Risks of ICC and NHL were assessed using Cox proportional hazards regression models. After a mean of 6.91 years of follow-up, there were 18 cases of ICC and 192 cases of NHL, including 99 cases of diffuse large B-cell lymphoma (DLBCL). Incidence rates of ICC were 0.09 and 0.43 per 100,000 person-years, respectively, among women who were hepatitis B surface antigen ...
Intrahepatic cholangiocarcinoma (ICC) is an aggressive, highly lethal tumors and lacks of effective chemo and targeted therapies. Cell lines and animal models, even partially reflecting tumor characteristics, have limits to study ICC biology and drug response. In this work, we created and characterized a novel ICC patient-derived xenograft (PDX) model of Italian origin. Seventeen primary ICC tumors derived from Italian patients were implanted into NOD (Non-Obese Diabetic)/Shi-SCID (severe combined immunodeficient) mice. To verify if the original tumor characteristics were maintained in PDX, immunohistochemical (cytokeratin 7, 17, 19, and epithelial membrane antigen) molecular (gene and microRNA expression profiling) and genetic analyses (comparative genomic hybridization array, and mutational analysis of the kinase domain of EGFR coding sequence, from exons 18 to 21, exons 2 to 4 of K-RAS, exons 2 to 4 of N-RAS, exons 9 and 20 of PI3KCA, and exon 15 of B-RAF) were performed after tumor stabilization.
Postoperative Mortality after Liver Resection for Perihilar Cholangiocarcinoma: Development of a Risk Score and Importance of Biliary Drainage of the Future Liver Remnant.
Cholangiocarcinomas are a heterogeneous group of malignancies arising from a number of cells of origin along the biliary tree. Although most cases in Western countries are sporadic, large population-based studies have identified a number of risk factors. This review summarises the evidence behind reported risk factors and current understanding of the molecular pathogenesis of cholangiocarcinoma, with a focus on inflammation and cholestasis as the driving forces in cholangiocarcinoma development. Cholestatic liver diseases (e.g. primary sclerosing cholangitis and fibropolycystic liver diseases), liver cirrhosis, and biliary stone disease all increase the risk of cholangiocarcinoma. Certain bacterial, viral or parasitic infections such as hepatitis B and C and liver flukes also increase cholangiocarcinoma risk. Other risk factors include inflammatory disorders (such as inflammatory bowel disease and chronic pancreatitis), toxins (e.g. alcohol and tobacco), metabolic conditions (diabetes, obesity and non
SCOTTSDALE, Ariz. - In what is a rare occurrence for all but a handful of U.S. medical centers, Mayo Clinic in Arizona is treating a life-threatening cancer of the bile duct by performing a liver transplant - an aggressive protocol that is exhibiting dramatic increases in survival rates, offering new hope for patients with this complex disease.. Mayo Clinic is one of only two liver transplant programs in the region of the U.S. that encompasses Arizona, California, Utah, Nevada and New Mexico performing liver transplants to treat Cholangiocarcinoma, a relatively rare bile duct cancer.. Moreover, Mayo Clinic is the only medical center doing living donor liver transplantation as a treatment protocol for Cholangiocarcinoma. In such a procedure, a healthy person donates half or slightly more of his or her liver to a family member or close friend who otherwise would be on a waiting list. Living donor liver transplants are performed because of the increased number of patients on the liver transplant ...
Expertise, Disease and Conditions: Bile Duct Cancer, Bile Duct Disease, Bile Duct Repair, Bile Duct Surgery, Bile Duct Tumors, Biliary Tract Surgery, Biliary Tree, Colorectal Metastases to the Liver, Distal Pancreatectomy, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Cancers, Gastrointestinal Diseases, General Surgery, Hepatic Surgery, Hepatobiliary Disease, Hepatobiliary Malignancies, Hepatobiliary Surgery, Hepatocellular Cancer, Hepatopancreatobiliary Surgery, Klatskin Tumors, Laparoscopic Adrenal Surgery, Laparoscopic Cholecystectomy, Laparoscopic Gallbladder Surgery, Laparoscopic Liver Surgery, Laparoscopic Pancreas Surgery, Liver Cancer, Liver Cysts, Liver Tumors, Minimally Invasive Surgery, Neuroendocrine Tumors, Pancreatic Cancer, Pancreatic Cysts, Pancreatic Disease, Pancreatic Surgery, Pancreatic Tumors, Pancreaticoduodenectomy, Retroperitoneal Sarcomas, Robotic Bilary Surgery, Robotic Liver Surgery, Robotic Pancreas Surgery, Stomach Cancer, Stomach Tumors, Surgical Oncology, ...
Cholangiocarcinoma (CCA) is the second most common liver cancer and it is associated with a poor prognosis. CCA can be divided into intrahepatic, hilar and distal. Despite the subtype, the median survival is 12-24 months without treatment. Liver transplantation (LT) is worldwide recognized as a curative option for hepatocellular carcinoma. On the other hand, the initial results for LT for CCA were very poor mainly due to a lack of adequate patient selection. In the last two decades, improvement has been made in the management of unresectable hilar CCA, and the results of LT after neoadjuvant chemoradiation have been shown to be promising ...
Histamine regulates functions via four receptors (HRH1, HRH2, HRH3, and HRH4). The d-myo-inositol 1,4,5-trisphosphate (IP3)/Ca2+/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates cholangiocarcinoma growth. We evaluated the role of HRH3 in the regulation of cholangiocarcinoma growth. Expression of HRH3 in intrahepatic and extrahepatic cell lines, normal cholangiocytes, and human tissue arrays was measured. In Mz-ChA-1 cells stimulated with (R)-(α)-(−)-methylhistamine dihydrobromide (RAMH), we measured (a) cell growth, (b) IP3 and cyclic AMP levels, and (c) phosphorylation of PKC and mitogen-activated protein kinase isoforms. Localization of PKCα was visualized by immunofluorescence in cell smears and immunoblotting for PKCα in cytosol and membrane fractions. Following knockdown of PKCα, Mz-ChA-1 cells were stimulated with RAMH before evaluating cell growth and extracellular signal-regulated kinase (ERK)-1/2 phosphorylation. In vivo experiments were done in BALB/c ...
A110 Cholangiocarcinoma (CCA), a malignant tumor of the bile duct epithelium, is one of the major of cancers in Northeast Thailand. This disease is difficult to diagnose and has a high mortality rate, thus posing an important public health problem in this region. Generally, cancer arises from dysregulation of tumor suppressor genes and oncogenes. c-Met, hepatocyte growth factor (HGF) receptor, and its ligand, HGF, regulate diverse biological responses including proliferation, migration and invasion, key features of metastatic cancer. Overexpression of c-Met has frequently been found in cholangiocarcinoma especially of well-differentiated type suggesting the role of c-Met in cholangiocarcinogenesis. In this study the role of HGF in invasiveness of cholangiocarcinoma was investigated using the human CCA cell line, KKU-213, in which c- Met expression is high when compare to immortalized cholangiocyte, H-69. Activation of c-Met by HGF induced KKU-213 cell proliferation, invasion and motility. ...
Sigma-Aldrich offers abstracts and full-text articles by [Maiko Terada, Kenichi Horisawa, Shizuka Miura, Yasuo Takashima, Yasuyuki Ohkawa, Sayaka Sekiya, Kanae Matsuda-Ito, Atsushi Suzuki].
Carcinoid tumors of the extrahepatic bile duct. A rare cause of malignant biliary obstruction.: Carcinoid tumor of the bile duct is a rare form of malignant bil
In the west, the exact cause of cholangiocarcinoma is unclear. It is likely that this cancer arises due to a combination of factors, including other illnesses that cause chronic damage to the liver and/or bile ducts, certain toxins and possibly a small genetic predisposition, although it is not believed to be a directly inherited disease. Although most cases of cholangiocarcinoma are in people over 60 years of age, it appears to be increasing across all age groups including younger people. The cause of this ongoing rise is currently unknown.. In Southeast Asia, especially Thailand, which has the worlds highest incidence of cholangiocarcinoma, associated risk factors include eating raw fish infected with liver fluke and chronic typhoid, neither of which occurs in the western world.. ...
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage ...
Periampullary cancers encompass a mixture of cancers but in general are separated into four subtypes: cancer in the head of the pancreas, distal bile duct cancer, true ampullary cancer, and duodenal cancer. These cancers arise in the vicinity of the ampulla of Vater and are differentiated by their histologic origins (pancreatic, distal bile duct, ampulla of Vater, or duodenum). While pancreatic adenocarcinoma makes up the majority of resected periampullary cancers at 62%, ampullary cancer accounts for 19%, distal bile duct cancer 12%, and duodenal cancer 7% of resected periampullary cancers.1 Although preoperative assessment with imaging and biopsy can distinguish one subtype from the other, often times the tumor origin may be undetermined preoperatively. Moreover, duodenal cancer in the periampullary region as well as intestinal-type ampullary cancer behave in a similar fashion, whereas distal bile duct cancer and pancreaticobiliary-type ampullary cancer behave similar to one another. While 56% ...
TY - JOUR. T1 - Extrahepatic bile duct obstruction and erosive disruption by cavitating porta hepatis nodal metastasis, treated by uncovered Wallstent. AU - Trambert, Jonathan J.. AU - Frost, Andrei. AU - Malasky, Charlotte. PY - 2004/7. Y1 - 2004/7. N2 - A 45-year-old woman with advanced gastric carcinoma presented with obstructive jaundice. Percutaneous transhepatic cholangiography (PTC) revealed erosive disruption of the extrahepatic bile ducts by a cavitating metastasis in the porta hepatis, as well as a biliary-duodenal fistula. External-internal biliary drainage via the fistula was plagued by recurrent drain occlusion by necrotic debris. This was ultimately alleviated by successful catheterization of the distal common bile duct (CBD) through the cavity, and linking the common hepatic duct (CHD) and CBD with a Wallstent, across the cavity. This succeeded in improving internal biliary drainage and isolating the exfoliating debris of the cavity from the bile ducts.. AB - A 45-year-old woman ...
Human intrahepatic biliary epithelial cells were isolated from the livers of patients with primary biliary cirrhosis and from normal livers and established in primary culture. The in vitro expression of intercellular adhesion molecule-1, HLA class I, and HLA class II on biliary epithelial cells was studied in response to tumour necrosis factor-alpha (0-500 U/ml), interferon-gamma (0-500 U/ml), and interleukin-1 (0-5 U/ml) by immunohistochemical staining and a semiquantitative scoring system validated by spectrophotometry and previously validated by laser confocal microscopy. The non-stimulated expression of intercellular adhesion molecule-1 and HLA class II was higher on cells derived from the primary biliary cirrhosis liver than on cells from normal liver, a difference not seen with HLA class I expression. A statistically significant increase in intercellular adhesion molecule-1 expression was seen with all three cytokines in cells derived from both primary biliary cirrhosis and normal liver. ...
TY - JOUR. T1 - Primary sclerosing cholangitis and pregnancy. AU - Landon, M. B.. AU - Soloway, R. D.. AU - Freedman, L. J.. AU - Gabbe, S. G.. PY - 1987. Y1 - 1987. N2 - Primary sclerosing cholangitis is a chronic, fibrosing, inflammatory disorder of unknown etiology affecting the biliary tree. We describe a case of a pregnancy complicated by this condition. Remarkably, maternal cholestasis improved with advancing gestation. Despite a marked elevation of bile acid levels in cord blood, the patient was delivered of a healthy term infant. The principles of management and potential effects of primary sclerosing cholangitis on pregnancy care are discussed.. AB - Primary sclerosing cholangitis is a chronic, fibrosing, inflammatory disorder of unknown etiology affecting the biliary tree. We describe a case of a pregnancy complicated by this condition. Remarkably, maternal cholestasis improved with advancing gestation. Despite a marked elevation of bile acid levels in cord blood, the patient was ...
Multistep processes likely underlie cholangiocarcinogenesis induced by chronic infection with the fish-borne liver fluke, Opisthorchis viverrini. One process appears to be cellular proliferation of the host bile duct epithelia driven by excretory-secretory (ES) products of this pathogen. Specifically, the secreted growth factor Ov-GRN-1, a liver fluke granulin, is a prominent component of ES and a known driver of hyper-proliferation of cultured human and mouse cells in vitro. We show potent hyper-proliferation of human cholangiocytes induced by low nanomolar levels of recombinant Ov-GRN-1 and similar growth produced by low microgram concentrations of ES products and soluble lysates of the adult worm. To further explore the influence of Ov-GRN-1 on the flukes and the host cells, expression of Ov-grn-1 was repressed using RNA interference. Expression of Ov-grn-1 was suppressed by 95% by day 3 and by ~100% by day 7. Co-culture of Ov-grn-1 suppressed flukes with human cholangiocyte (H-69) or human ...
TY - JOUR. T1 - Clinical features and management of primary sclerosing cholangitis. AU - Silveira, Marina G.. AU - Lindor, Keith. PY - 2008. Y1 - 2008. N2 - Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts, resulting in cirrhosis and need for liver transplantation and reduced life expectancy. The majority of cases occur in young and middle-aged men, often in association with inflammatory bowel disease. The etiology of primary sclerosing cholangitis includes immune-mediated components and elements of undefined nature. No effective medical therapy has been identified. The multiple complications of primary sclerosing cholangitis include metabolic bone disease, dominant strictures, bacterial cholangitis, and malignancy, particularly cholangiocarcinoma, which is the most lethal complication of primary sclerosing cholangitis. Liver transplantation is currently the only life-extending therapeutic alternative for patients ...

*List of hepato-biliary diseases

Malignant neoplasm of liver and intrahepatic bile ducts. The most frequent forms are metastatic malignant neoplasm of liver) ... of liver malignant neoplasm of the gallbladder malignant neoplasm of other parts of biliary tract extrahepatic bile duct ... hepatoma cholangiocarcinoma hepatoblastoma angiosarcoma of liver Kupffer cell sarcoma other sarcomas of liver Benign neoplasm ...

*C22

... a freshwater catfish Malignant neoplasms of liver and intrahepatic bile ducts ICD-10 code Centre Municipal Airport FAA LID. ...

*List of MeSH codes (C04)

... biliary tract neoplasms MeSH C04.588.274.120.250 --- bile duct neoplasms MeSH C04.588.274.120.250.250 --- common bile duct ... nose neoplasms MeSH C04.588.149.721.656 --- orbital neoplasms MeSH C04.588.149.721.828 --- skull base neoplasms MeSH C04.588. ... anal gland neoplasms MeSH C04.588.274.476.411.445 --- duodenal neoplasms MeSH C04.588.274.476.411.501 --- ileal neoplasms MeSH ... femoral neoplasms MeSH C04.588.149.721 --- skull neoplasms MeSH C04.588.149.721.450 --- jaw neoplasms MeSH C04.588.149.721. ...

*List of MeSH codes (C06)

... common bile duct neoplasms MeSH C06.130.320.120 --- bile duct neoplasms MeSH C06.130.320.120.280 --- common bile duct neoplasms ... bile duct neoplasms MeSH C06.301.120.250.250 --- common bile duct neoplasms MeSH C06.301.120.401 --- gallbladder neoplasms MeSH ... File "2006 MeSH Trees".) MeSH C06.130.120.120 --- bile duct neoplasms MeSH C06.130.120.120.280 --- common bile duct neoplasms ... anal gland neoplasms MeSH C06.301.371.411.445 --- duodenal neoplasms MeSH C06.301.371.411.501 --- ileal neoplasms MeSH C06.301. ...

*Pancreatic serous cystadenoma

... a yellowing of the skin and eyes caused by obstruction of the bile duct), or weight loss. These signs and symptoms are not ... such as the intraductal papillary mucinous neoplasm and the mucinous cystic neoplasm), serous cystic neoplasms are almost ... mixed serous-endocrine neoplasm, and VHL-associated serous cystic neoplasm. This latter classification scheme is useful because ... Once a doctor has reason to believe that a patient may have serous cystic neoplasm, he or she can confirm that suspicion using ...

*Biliary disease

malignant neoplasm of the gallbladder malignant neoplasm of other parts of biliary tract extrahepatic bile duct ampulla of ...

*Cholangiocarcinoma

Patient information on extrahepatic bile duct tumors, from the National Cancer Institute. Cancer.Net: Bile Duct Cancer The ... Cholangiocarcinoma is a relatively rare neoplasm that is classified as an adenocarcinoma (a cancer that forms glands or ... Tumors occurring in the bile ducts within the liver are referred to as intrahepatic, those occurring in the ducts outside the ... Chronic inflammation and obstruction of the bile ducts, and the resulting impaired bile flow, are thought to play a role in ...

*Clonorchiasis

The parasitic worm is as long as 10 to 25mm and lives in the bile ducts of the liver. The eggs of the worms are passed through ... Clonorchiasis is a known risk factor for the development of cholangiocarcinoma, a neoplasm of the biliary system. Symptoms of ...

*Nucleoporin

... which inhibit p62 complexes have links to primary biliary cirrhosis which destroys the bile ducts of the liver. Decreases in ... is commonly found in precancerous dysplasias and malignant neoplasms. Each individual nucleoporin is named according to its ...

*ICD-10 Chapter II: Neoplasms

Malignant neoplasms of liver and intrahepatic bile ducts (C22.0) Liver cell carcinoma (C22.1) Intrahepatic bile duct carcinoma ... Liver Intrahepatic bile ducts (D13.5) Extrahepatic bile ducts (D13.6) Pancreas (D13.7) Endocrine pancreas Islet cell tumour ... Neoplasms. (C00) Malignant neoplasm of lip (C01) Malignant neoplasm of base of tongue (C02) Malignant neoplasm of other and ... Malignant neoplasm of breast (C51) Malignant neoplasm of vulva (C52) Malignant neoplasm of vagina (C53) Malignant neoplasm of ...

*Intraductal papillary mucinous neoplasm

... a yellowing of the skin and eyes caused by obstruction of the bile duct), weight loss, and acute pancreatitis. These signs and ... Intraductal papillary mucinous neoplasm (IPMN) is a type of tumor that can occur within the cells of the pancreatic duct. IPMN ... Pancreatic mucinous cystic neoplasm Pancreatic serous cystadenoma Solid pseudopapillary neoplasm "Intraductal Papillary ... These tests will reveal dilatation of the pancreatic duct or one of the branches of the pancreatic duct. In some cases a fine ...

*Intraductal papillary neoplasm of the bile duct

... , also known as intraductal papillary biliary neoplasm, is a rare type of liver ...

*List of ICD-9 codes 140-239: neoplasms

Malignant neoplasm of liver and intrahepatic bile ducts (156) Malignant neoplasm of gallbladder and extrahepatic bile ducts ( ... Benign neoplasm of kidney and other urinary organs (224) Benign neoplasm of eye (225) Benign neoplasm of brain and other parts ... Malignant neoplasm of gum (144) Malignant neoplasm of floor of mouth (145) Malignant neoplasm of other and unspecified parts of ... Malignant neoplasm of eye (191) Malignant neoplasm of brain (192) Malignant neoplasm of other and unspecified parts of nervous ...

*Digestive system neoplasm

bile duct: Cholangiocarcinoma. *Klatskin tumor. *gallbladder: Gallbladder cancer. Pancreas. *exocrine pancreas: Adenocarcinoma ... This article about a neoplasm is a stub. You can help Wikipedia by expanding it.. *v ... Retrieved from "https://en.wikipedia.org/w/index.php?title=Digestive_system_neoplasm&oldid=898746878" ...

*David B. Adams

Dixon, J. A.; Morgan, K. A.; Adams, D. B. (2009). "Management of common bile duct injury during partial gastrectomy". The ... Ellis, C. T.; Barbour, J. R.; Shary, T. M.; Adams, D. B. (2010). "Pancreatic cyst: Pseudocyst or neoplasm? Pitfalls in ... Theruvath, T. P.; Morgan, K. A.; Adams, D. B. (2010). "Mucinous cystic neoplasms of the pancreas: How much preoperative ...

*Gastrinoma

Most gastrinomas are found in the gastrinoma triangle; this is bound by the junction of cystic and common bile ducts, junction ... Pancreatic Endocrine Neoplasms webpage Surgery Questions on gastrinoma Gastrinoma Triangle. ...

*Pancreatic mass

... an abnormal yellowing of the skin and eyes often caused by blockage of the bile ducts) are more likely to have a pancreatic ... Some cysts are cancerous, and others, such as the intraductal papillary mucinous neoplasm (IPMN) are potentially precancerous. ... MRI is a great method to visualize the pancreatic ducts, PET scanning can reveal the metabolic activity of a tumor, EUS ... and ERCP can be used to visualize the duct system of the pancreas and stents (small tubes to re-establish the flow of ...

*Liver cancer

... can also form from other structures within the liver such as the bile duct, blood vessels and immune cells. Cancer ... Less common types include mucinous cystic neoplasm and intraductal papillary biliary neoplasm. The diagnosis may be supported ... The majority of cholangiocarcimas occur in the hilar region of the liver, and often present as bile duct obstruction. If the ... "SEER Stat Fact Sheets: Liver and Intrahepatic Bile Duct Cancer". NCI. Archived from the original on 2017-07-28. Retrieved 2016 ...

*List of cancer types

... gastrointestinal Colon cancer Extrahepatic bile duct cancer Gallbladder cancer Gastric (stomach) cancer Gastrointestinal ... Marginal zone B-cell lymphoma Mast cell leukemia Mediastinal large B cell lymphoma Multiple myeloma/plasma cell neoplasm ... which suggests that it has originated in the milk ducts.[citation needed] Benign tumors (which are not cancers) are usually ...

*Hepatotoxicity

Injury to hepatocyte and bile duct cells lead to accumulation of bile acid inside the liver. This promotes further liver damage ... Oral contraceptives Neoplasm Neoplasms have been described with prolonged exposure to some medications or toxins. ... it can produce features similar to primary biliary cirrhosis due to progressive destruction of small bile ducts (Vanishing duct ... diclofenac Cholestasis Liver injury leads to impairment of bile flow and cases are predominated by itching and jaundice. ...

*Pseudomyxoma peritonei

Other primary sites that have been reported include colon, rectum, stomach, gallbladder, bile ducts, small intestine, urinary ... For example, neoplasms characterized by high-grade features, invasive glands and or signet ring cells, are termed ... Young R (2004). "Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms". Semin Diagn Pathol ... Sugarbaker P (2006). "New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?". Lancet ...

*Sarcoma botryoides

... common bile duct, urinary bladder of infants and young children or the vagina in females, typically younger than age 8. The ... Neoplasms of the Vulva and Vagina. in Holland-Frei Cancer Medicine - 6th Ed. Kufe, DW et al. editors. BC Decker Inc., Hamilton ...

*Pancreatic cancer

This results when a cancer in the head of the pancreas obstructs the common bile duct as it runs through the pancreas.[30] ... "Islet Cell Tumors of the Pancreas / Endocrine Neoplasms of the Pancreas". The Sol Goldman Pancreas Cancer Research Center. ... Liver function tests can show a combination of results indicative of bile duct obstruction (raised conjugated bilirubin, γ- ... and attaching a loop of jejunum to the cystic duct to drain bile ("cholecysto-jejunostomy"). It can be performed only if the ...

*Index of oncology articles

... common bile duct - comorbidity - compassionate use trial - complementary and alternative medicine - complete blood count (CBC ... neoplasm - nephrotomogram - nephrotoxic - nephroureterectomy - nerve block - nerve grafting - nerve-sparing radical ... bile duct - biliary - bilirubin - binding agent - bioavailable - biochanin A - biochemical reactions - biological response ... intrahepatic bile ducts - intrahepatic infusion - intralesional - intraluminal intubation and dilation - Intramuscular ...

*ICD-10 Chapter XI: Diseases of the digestive system

Obstruction of bile duct (K83.2) Perforation of bile duct (K83.3) Fistula of bile duct (K83.4) Spasm of sphincter of Oddi ( ... Neoplasms (C00-D49) Symptoms, signs, and abnormal clinical and laboratory findings, NEC (R00-R94) List of ICD-10 codes ... Calculus of bile duct with cholangitis (K80.4) Calculus of bile duct with cholecystitis (K80.5) Calculus of bile duct without ...

*Juvenile polyposis syndrome

bile duct: Cholangiocarcinoma. *Klatskin tumor. *gallbladder: Gallbladder cancer. Pancreas. *exocrine pancreas: Adenocarcinoma ... cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm. *Mucinous cystic neoplasm ... AMHR2 (Persistent Müllerian duct syndrome II). *TGF beta receptors: Endoglin/Alk-1/SMAD4 (Hereditary hemorrhagic telangiectasia ...

*Carcinoid

bile duct: Cholangiocarcinoma. *Klatskin tumor. *gallbladder: Gallbladder cancer. Pancreas. *exocrine pancreas: Adenocarcinoma ... cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm. *Mucinous cystic neoplasm ...

*Cronkhite-Canada syndrome

bile duct: Cholangiocarcinoma. *Klatskin tumor. *gallbladder: Gallbladder cancer. Pancreas. *exocrine pancreas: Adenocarcinoma ... cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm. *Mucinous cystic neoplasm ...

Extrahepatic biliary cystadenoma with mesenchymal stroma: a true biliary cystadenoma? A case report.Extrahepatic biliary cystadenoma with mesenchymal stroma: a true biliary cystadenoma? A case report.

Biliary cystadenomas are benign but potentially malignant cystic neoplasms, which classically contain mesenchymal stroma ... Bile Duct Neoplasms / complications, diagnosis*, surgery. Cystadenoma / complications, diagnosis*, surgery. Female. ... Hepatic Duct, Common*. Humans. Middle Aged. Ovarian Neoplasms / complications, diagnosis*, secondary, surgery. Tomography, X- ... Computerized Tomography identified a complex multi-locular cyst in the common hepatic duct. Radical excision of the lesion and ...
more infohttp://www.biomedsearch.com/nih/Extrahepatic-biliary-cystadenoma-with-mesenchymal/21725521.html

Pancreatic Cancer Blog  » Blog Archive   » Pancreatic Endocrine Neoplasms, Part 2Pancreatic Cancer Blog » Blog Archive » Pancreatic Endocrine Neoplasms, Part 2

... a yellowing of the skin caused by blockage of the bile duct). The diagnosis can often be suggested on CT scan, as most ... Pancreatic Endocrine Neoplasms, Part 2. Most pancreatic endocrine neoplasms are non-syndromic, that is they do not produce a ... One Response to "Pancreatic Endocrine Neoplasms, Part 2". * Jim Epperlein. Says: August 6th, 2010 at 5:18 pm Thanks so much for ... The 5-year survival rate for patients with a non-syndromic pancreatic endocrine neoplasm is 65%, and the ten-year survival rate ...
more infohttp://apps.pathology.jhu.edu/blogs/pancreas/?p=64

Intraductal papillary neoplasm of the bile duct - WikipediaIntraductal papillary neoplasm of the bile duct - Wikipedia

Intraductal papillary neoplasm of the bile duct, also known as intraductal papillary biliary neoplasm, is a rare type of liver ...
more infohttps://en.wikipedia.org/wiki/Intraductal_papillary_neoplasm_of_the_bile_duct

Intraductal papillary neoplasm in common bile duct opening into the stomachIntraductal papillary neoplasm in common bile duct opening into the stomach

... but its recognition may help identify the cause of certain clinical conditions and prevent bile duct injury during surgery if ... but its recognition may help identify the cause of certain clinical conditions and prevent bile duct injury during surgery if ... More News: Bile , Computers , CT Scan , ERCP , Gastrectomy , Gastroenterology , Jaundice , Pancreas , Pathology , PET Scan , ... Possible causes include bacterial sepsis, galactosemia, tyrosinemia, panhypo-pituitarism, bile acid synthetic defects, ...
more infohttps://medworm.com/779440935/intraductal-papillary-neoplasm-in-common-bile-duct-opening-into-the-stomach/

Bile duct neoplasms Pathway Map - PrimePCR | Life Science | Bio-RadBile duct neoplasms Pathway Map - PrimePCR | Life Science | Bio-Rad

Bile duct neoplasms H96 Predesigned 96-well panel for use with SYBR® Green ... Bile duct neoplasms H384 Predesigned 384-well panel for use with SYBR® Green ... Bile duct neoplasms M96 Predesigned 96-well panel for use with SYBR® Green ... Bile duct neoplasms M384 Predesigned 384-well panel for use with SYBR® Green ...
more infohttp://www.bio-rad.com/en-us/prime-pcr-assays/pathway/bile-duct-neoplasms

Common bile duct neoplasms | Article about Common bile duct neoplasms by The Free DictionaryCommon bile duct neoplasms | Article about Common bile duct neoplasms by The Free Dictionary

The duct formed by the union of the hepatic and cystic ducts Explanation of Common bile duct neoplasms ... Find out information about Common bile duct neoplasms. ... common bile duct. (redirected from Common bile duct neoplasms) ... Related to Common bile duct neoplasms: Bile duct cancer. common bile duct. [¦käm·ən ′bīl ‚dəkt] (anatomy) The duct formed by ... Common bile duct neoplasms , Article about Common bile duct neoplasms by The Free Dictionary https://encyclopedia2. ...
more infohttp://encyclopedia2.thefreedictionary.com/Common+bile+duct+neoplasms

Erlotinib Completed Phase 1 Trials for Extrahepatic Bile Duct Cancer / Small Intestine Cancer / Gallbladder Cancer / Malignant...Erlotinib Completed Phase 1 Trials for Extrahepatic Bile Duct Cancer / Small Intestine Cancer / Gallbladder Cancer / Malignant...

Malignant Neoplasm of Pancreas / Periampullary Adenocarcinoma / Liver Cancer Treatment. Back to Erlotinib ... Erlotinib Completed Phase 1 Trials for Extrahepatic Bile Duct Cancer / Small Intestine Cancer / Gallbladder Cancer / ...
more infohttps://www.drugbank.ca/drugs/DB00530/clinical_trials?conditions=DBCOND0028665%2CDBCOND0028579%2CDBCOND0028488%2CDBCOND0087260%2CDBCOND0042952%2CDBCOND0028490&phase=1&purpose=treatment&status=completed

CT imaging comparison between intraductal papillary neoplasms of the bile duct and papillary cholangiocarcinomas |...CT imaging comparison between intraductal papillary neoplasms of the bile duct and papillary cholangiocarcinomas |...

Intraductal papillary neoplasm of the bile duct (IPNB) was first described by Chen et al in 2001 as a biliary papillary tumor ... Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the ... downstream bile duct dilatation, and the lack of abnormal enhancement in the adjacent bile duct. Interestingly, two patients ... developed in intrahepatic bile ducts, and 41/48 PCCs (85%) in the distal bile duct. Cystic appearance was highly suggestive for ...
more infohttps://www.springermedizin.de/ct-imaging-comparison-between-intraductal-papillary-neoplasms-of/16316558

2020 ICD-10-CM Codes C22*: Malignant neoplasm of liver and intrahepatic bile ducts2020 ICD-10-CM Codes C22*: Malignant neoplasm of liver and intrahepatic bile ducts

C15-C26 Malignant neoplasms of digestive organs › Malignant neoplasm of liver and intrahepatic bile ducts C22- >. Use ... Secondary malignant neoplasm of liver and intrahepatic bile duct. 2016 2017 2018 2019 2020 Billable/Specific Code ... C22 Malignant neoplasm of liver and intrahepatic bile ducts* C22.0 Liver cell carcinoma ... secondary malignant neoplasm of liver and intrahepatic bile duct (. ICD-10-CM Diagnosis Code C78.7 ...
more infohttps://www.icd10data.com/ICD10CM/Codes/C00-D49/C15-C26/C22-

Intraductal papillary neoplasm of the bile duct: Assessment of invasive carcinoma and long-term outcomes using MRI | SNFGE.org ...Intraductal papillary neoplasm of the bile duct: Assessment of invasive carcinoma and long-term outcomes using MRI | SNFGE.org ...

Intraductal papillary neoplasm of the bile duct: Assessment of invasive carcinoma and long-term outcomes using MRI ... Imaging characteristics for discriminating the malignant potential of intraductal papillary neoplasm of the bile duct (IPNB) ... Significant magnetic resonance imaging findings that differentiated between an intraductal papillary neoplasm of the bile duct ... bile duct wall thickening, and adjacent organ invasion (all p ≤0.002). The 1-, 3-, and 5-year RFS rates for surgically resected ...
more infohttps://www.snfge.org/content/intraductal-papillary-neoplasm-bile-duct-assessment-invasive-carcinoma-and-long-term

A previously undescribed form of intraductal papillary neoplasm of the bile duct. - Semantic ScholarA previously undescribed form of intraductal papillary neoplasm of the bile duct. - Semantic Scholar

... bile duct (● Fig.3). The filling defect in the intrahepatic bile duct was considered to be mucin. Therefore, we diagnosed this ... examination showed a malignant papillary proliferation within the dilated B4 bile duct and invasion into the bile duct wall on ... this tumor causes cystic dilation of the affected bile ducts as well as branched-type intraductal mucinous papillary neoplasm ... We herein report the first case of an IPNB occurring in an extrahepatic site communicating with the intrahepatic bile duct. The ...
more infohttps://www.semanticscholar.org/paper/A-previously-undescribed-form-of-intraductal-of-the-Ogura-Kurisu/d05f675f3361d62def2f43166fffad9c7b4d1452

Intraductal papillary neoplasm of the bile duct: A biliary equivalent to intraductal papillary mucinous neoplasm of the...Intraductal papillary neoplasm of the bile duct: A biliary equivalent to intraductal papillary mucinous neoplasm of the...

Intraductal papillary neoplasm of the bile duct: A biliary equivalent to intraductal papillary mucinous neoplasm of the ... Pancreatic Neoplasms abstract * IPNBs are an uncommon variant of bile duct cancer, representing approximately 10% of all ... and may represent a carcinogenesis pathway different from that of conventional bile duct carcinomas arising from flat dysplasia ...
more infohttp://vivo.med.cornell.edu/display/pubid84867205475

Common Bile Duct Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical TrialsCommon Bile Duct Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MalaCards based summary : Common Bile Duct Neoplasm, is also known as common bile duct neoplasms. Affiliated tissues include ... MalaCards integrated aliases for Common Bile Duct Neoplasm:. Name: Common Bile Duct Neoplasm 12 17 ... Search GEO for disease gene expression data for Common Bile Duct Neoplasm. ... Prospective Multicenter Evaluation of a New Short-access-cholangioscope for Biliary Duct Strictures and Gall Stones. Completed ...
more infohttps://www.malacards.org/card/common_bile_duct_neoplasm

BILE DUCT NEOPLASMS | SelfDecode | Genome AnalysisBILE DUCT NEOPLASMS | SelfDecode | Genome Analysis

Use SelfDecode to get personalized health recommendations based on your genes. Get started today with an existing DNA file or order a SelfDecode DNA kit!
more infohttps://selfdecode.com/disease/bile-duct-neoplasms/

Intraductal Papillary Neoplasms of the Bile DuctIntraductal Papillary Neoplasms of the Bile Duct

... is a rare variant of bile duct tumors characterized by papillary growth within the bile duct lumen and is regarded as a biliary ... The most common radiologic findings for IPNB are bile duct dilatation and intraductal masses. The major treatment of IPNB is ... counterpart of intraductal papillary mucinous neoplasm of the pancreas. IPNBs display a spectrum of premalignant lesion towards ... Intraductal papillary neoplasm of the bile duct (IPNB) ... Intraductal Papillary Neoplasms of the Bile Duct. Masayuki ...
more infohttps://new.hindawi.com/journals/ijh/2014/459091/

Intraductal Papillary Mucinous Neoplasms of the Bile Duct Treated with Argon Plasma Coagulation  | Korean Journal of Pancreas...Intraductal Papillary Mucinous Neoplasms of the Bile Duct Treated with Argon Plasma Coagulation | Korean Journal of Pancreas...

Bile Duct Neoplasms , Bile Ducts , Bile , Comorbidity , Dilatation , Epithelium , Female , Hepatic Duct, Common , Humans , ... Full text: Available Index: WPRIM (Western Pacific) Main subject: Argon / Bile / Bile Duct Neoplasms / Bile Ducts / Aged / ... Intraductal papillary mucinous neoplasm of the bile duct (IPMN-B) is frequently found and has recently been recognized as a ... Intraductal Papillary Mucinous Neoplasms of the Bile Duct Treated with Argon Plasma Coagulation / 대한췌담도학회지 ...
more infohttps://search.bvsalud.org/gim/resource/en/wprim-143194

Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma - Full Text View -...Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma - Full Text View -...

Neoplasms by Histologic Type. Neoplasms. Adenocarcinoma. Liver Neoplasms. Digestive System Neoplasms. Neoplasms by Site. ... Experimental: HCC with bile duct invasion Photodynamic therapy with biliary drainage in patients with bile duct invasion of ... Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma. The safety and scientific ... Survival time was defined as the duration from the date of imaging showing bile duct invasion of HCC to the date of death or to ...
more infohttps://clinicaltrials.gov/ct2/show/NCT01506115

extrahepatic bile duct neoplasm drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engineextrahepatic bile duct neoplasm drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine

MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / therapy. Bile Ducts, Extrahepatic. Bile Ducts, Intrahepatic ... MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic. Bile Ducts, ... Bile Duct Neoplasms / genetics. Bile Duct Neoplasms / pathology. Bile Ducts, Extrahepatic / pathology. Bile Ducts, Intrahepatic ... Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / mortality. ...
more infohttp://www.bmlsearch.com/?kwr=extrahepatic+bile+duct+neoplasm+drug+therapy+2000:2010%5Bpubdate%5D&cxts=100&stmp=b1

ICD-10 Diagnosis Code D13.5 Benign neoplasm of extrahepatic bile ductsICD-10 Diagnosis Code D13.5 Benign neoplasm of extrahepatic bile ducts

Short Description: Benign neoplasm of extrahepatic bile ducts Long Description: Benign neoplasm of extrahepatic bile ducts This ... common (bile) duct. C24.0. C78.89. D01.5. D13.5. D37.6. D49.0. »cystic (bile) duct (common). C24.0. C78.89. D01.5. D13.5. D37.6 ... your gallbladder pushes the bile into tubes called bile ducts. They carry the bile to your small intestine. The bile helps ... extrahepatic (bile) duct. C24.0. C78.89. D01.5. D13.5. D37.6. D49.0. »gall duct (extrahepatic). C24.0. C78.89. D01.5. D13.5. ...
more infohttps://icdlist.com/icd-10/d135

Diseases(malignant-neoplasm-of-liver-and-intrahepatic-bile-ducts) - Clinical PearlDiseases(malignant-neoplasm-of-liver-and-intrahepatic-bile-ducts) - Clinical Pearl

Clinical Pearl is a Continuous professional development platform with a precise and concise point of care clinical knowledge search engine and 360-degree learning cycle management platform for all healthcare professionals and organizations ...
more infohttps://clinicalpearl.com/Diseases/malignant-neoplasm-of-liver-and-intrahepatic-bile-ducts/

Research Keyword Faculty Listing | Yale School of MedicineResearch Keyword Faculty Listing | Yale School of Medicine

Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Common Bile Duct Diseases; Common Bile Duct Neoplasms; ... Barrett Esophagus; Bile Duct Neoplasms; Biliary Tract Diseases; Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; ... Ileal Neoplasms; Intestinal Neoplasms; Pancreatic Cyst; Pancreatic Diseases; Pancreatic Fistula; Pancreatic Neoplasms; ... Duodenal Neoplasms; Emphysematous Cholecystitis; Esophageal Cyst; Esophageal Diseases; Esophageal Fistula; Esophageal Neoplasms ...
more infohttps://medicine.yale.edu/research/listing.aspx?meshId=3000

Cholangiocarcinoma | Bile Duct Cancer: MedlinePlusCholangiocarcinoma | Bile Duct Cancer: MedlinePlus

Learn about bile duct cancer tests, diagnosis, treatment, and survival rates. ... Bile duct cancer can be caused by liver diseases or colitis. ... ClinicalTrials.gov: Bile Duct Neoplasms (National Institutes of ... Bile duct cancer is rare. It can happen in the parts of the bile ducts that are outside or inside the liver. Cancer of the bile ... your gallbladder pushes the bile into tubes called bile ducts. They carry the bile to your small intestine. The bile helps ...
more infohttps://medlineplus.gov/bileductcancer.html

GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.  - PubMed - NCBIGNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct. - PubMed - NCBI

GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.. Sasaki M1, Matsubara T, Nitta T, Sato ... with IPNB in intrahepatic and perihilar bile ducts (perihilar IPNB) and 6 patients (M/F = 5/1) with IPNB in distal bile ducts ( ... Intraductal papillary neoplasms of the bile duct (IPNB) shows favorable prognosis and is regarded as a biliary counterpart of ... Intraductal papillary neoplasms of the bile duct (IPNBs) with high- and low- mucin production and the expression profiles of ...
more infohttps://phgkb.cdc.gov/PHGKB/phgHome.action?action=forward&dbsource=huge&id=89522
  • BACKGROUND: Nonsurgical pathologic confirmation of malignant bile duct strictures is desirable for defining subsequent treatment and prognosis. (uptodate.com)
  • Farrell RJ, Jain AK, Brandwein SL, Wang H, Chuttani R, Pleskow DK (2001) The combination of stricture dilation, endoscopic needle aspiration, and biliary brushings significantly improves diagnostic yield from malignant bile duct strictures. (springer.com)
  • We examined the status of GNAS mutation at codon 201 and KRAS mutation at codon 12&13, degree of mucin production and immunohistochemical expressions of MUC mucin core proteins in 29 patients (M/F = 15/14) with IPNB in intrahepatic and perihilar bile ducts (perihilar IPNB) and 6 patients (M/F = 5/1) with IPNB in distal bile ducts (distal IPNB). (cdc.gov)
  • One major complication that occurred was perforation of the common hepatic duct with leakage of bile, which was managed by surgical oversewing. (uptodate.com)
  • Total excision of the cyst with adequate bile drainage is the standard treatment for choledochal cyst. (medscape.com)
  • Total excision of the cyst in types I, II, and IV followed by reconstruction of the biliary tree with hepaticojejunostomy in a Roux-en-Y fashion has been widely accepted as the procedure of choice in treating choledochal cysts and has been found to be superior to hepaticoduodenostomy. (medscape.com)
  • Several groups have successfully performed laparoscopic-assisted and laparoscopic total cyst excision with Roux-en-Y hepatoenterostomy with complication rates comparable to those of the open procedure. (medscape.com)
  • [ 57 ] Li et al performed laparoscopic cyst excision with laparoscopic-assisted Roux-en-Y hepatoenterostomy in 35 children (33 cyst type, two fusiform) without conversion to the open procedure and with postoperative stays of 3-5 days. (medscape.com)
  • Risk factors include having inflammation of the bile duct, ulcerative colitis , and some liver diseases. (medlineplus.gov)
  • As the graph below shows, the difference in the proportion of deaths due to Malignant neoplasms and Ischaemic heart diseases continues to widen since 1993. (abs.gov.au)